td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31190
[post_author] => 3410
[post_date] => 2026-01-19 11:11:00
[post_date_gmt] => 2026-01-19 00:11:00
[post_content] => A recent systematic review published in the BMJ has reignited debate about what happens when patients stop taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related GLP-1–based incretin therapies.
The analysis found that weight often returns quickly once treatment is discontinued – in some cases faster than with other weight-loss interventions.
And it’s not just weight that rebounds. Cardiometabolic risk markers, including blood pressure, blood glucose and blood lipids, were also found to revert towards pre-treatment levels.
As prescribing of these medicines continues to rise, the findings raise a broader question: should patients be starting these medicines in the first place?
AP spoke with experts to unpack the evidence.
Weight regain predictable, but not the real problem
Professor Clare Collins, Professor of Nutrition and Dietetics at the University of Newcastle, said the pattern of rapid weight regain following cessation was entirely unsurprising.
‘This is exactly what you would expect,’ she said.
[caption id="attachment_31196" align="aligncenter" width="400"]
Professor Clare Collins[/caption]
For Prof Collins, the findings reinforce a core principle of chronic disease management: when an effective treatment is withdrawn, the condition it was controlling usually returns.
‘If someone stops taking antihypertensives, what happens? Their blood pressure goes back up,’ she said.
‘While predictable, the deterioration back to baseline is why we need to be thinking much more carefully about what is needed for long-term maintenance.'
Prof clare collins
While weight regain attracts headlines, Prof Collins said the more clinically concerning signal is the deterioration in metabolic markers once treatment ceases.
‘While predictable, the deterioration back to baseline is why we need to be thinking much more carefully about what is needed for long-term maintenance.’
Not a sign of treatment failure
Associate Professor Trevor Steward, Director of the Melbourne School of Psychological Sciences’ Brain and Mental Health Hub, agrees that the rebound effect reflects how GLP-1 RA medicines work, rather than a failure of the drugs or patient behaviour.
Instead of creating permanent physiological change, GLP-1 RAs amplify hormonal signals that already exist in the body – particularly those involved in appetite regulation, digestion and satiety. The benefits seen during treatment depend on sustained exposure to these hormones.
[caption id="attachment_31197" align="aligncenter" width="400"]
Associate Professor Trevor Steward[/caption]
‘That's why we see this rapid rebound effect of people experiencing weight gain when they stop using them, because there’s no longer increased circulating levels of hormones impacting their different body systems,’ A/Prof Steward said.
However, the mechanisms behind the accelerated regain are not yet fully understood.
‘Some indications are that while these newer medications help people lose weight faster, they may cause a stronger slingshot effect,’ he said.
Prof Collins points to emerging evidence suggesting incretin therapies cross the blood–brain barrier, influencing reward pathways linked to appetite and environmental cues to eat.
‘For example, if you go to the supermarket for a loaf of bread and come back with donuts too – that’s what’s referred to as “food noise”,’ she said. ‘Some people say this [noise] really goes down when using these therapies.’
When treatment is withdrawn, the surrounding food environment can quickly reassert itself. This is where tapering, behavioural support and nutrition strategies become critical.
‘It may be that people are more receptive to maintenance support programs as they’re tapering or finding out what their maintenance medication dose is,’ she said. ‘If they’re aware of that point, they’ll recognise when the food noise starts again.’
Nutrition: the missing variable
Prof Collins recently led a systematic review which highlighted that changes in dietary intake and nutrition remain largely invisible in incretin trials.
‘Of all the phase three trials, only two actually measured and reported what people ate,’ she said.
Most trials provided standardised advice but did not collect data on dietary intake, leaving clinicians to infer how appetite suppression, nausea and early satiety shaped eating patterns over time.
‘They mostly worked with people to identify dietary changes that would remove about 2,000 kilojoules a day – enough to trigger weight loss,’ she said.
But reduced intake doesn’t automatically equate to improved diet quality or nutrient adequacy, with micronutrient deficiencies and loss of lean mass emerging if nutrition isn’t actively monitored.
With frequent patient contact, Prof Collins believes pharmacists are uniquely placed to identify emerging problems, intervene early and support appropriate referral to dietitians for medical nutrition therapy.
‘[And] if pharmacy staff are trained, they can say, “Hang on a minute, you need to talk to the pharmacist”.’
The University of Newcastle also has a suite of resources pharmacists could direct patients to, including a healthy eating quiz and obesity management podcast, available here.
When visible deterioration or rapid weight loss appears, referral becomes essential. ‘Once you think, “this person is fading before our eyes”, that’s when you alert the GP and refer to a dietitian,’ Prof Collins said.
Supporting persistence with therapy also plays a role in outcomes.
‘The main benefit isn’t weight – it’s metabolic health,’ she said. ‘Helping people manage [adverse] effects supports continuation.’
As weight loss occurs, pharmacists should also be alert to the need to review other medicines.
‘If someone is dropping weight rapidly, blood sugars and blood pressure can fall,’ she said. ‘There are also rare but potentially severe complications – pancreatitis, gallstones, bowel obstruction and non-arteritic anterior ischaemic optic neuropathy,’ she said. ‘Staying well hydrated is critical – urine should look straw-coloured.’
Playing the long game
A/Prof Steward said there’s now sufficient evidence to normalise weight regain after cessation. And given the established risks associated with long-term obesity, he suggests continued therapy may represent a lower-risk option for some patients.
‘As we know, having a very high BMI for a long period of time confers its own levels of risks in terms of cardiovascular disease and other issues,’ he said. ‘So [many clinicians] think it's worth staying on these [medicines] long term as opposed to the potential risk of weight [regain].’
For people with repeated cycles of weight loss and regain, A/Prof Steward said GLP-1 RAs are increasingly being understood as potentially lifelong treatments – similar to medicines used for other chronic conditions.
‘Clinicians want clearer evidence around tapering and maintenance – and right now, they’re operating in the dark.'
A/prof trevor steward
‘I recently had a conversation with someone who has lost over 50 kilograms three times in her life,’ he said. ‘After a sustained period of lifestyle change, the weight still comes back. She would rather stay on these medicines for life than put her body through that cycle again.’
As use expands, A/Prof Steward emphasised the importance of clarifying intent and expectations before treatment begins.
‘It's really important to have that conversation with a pharmacist or GP about whether they want to make that commitment to potentially taking these long term,’ he said.
This also creates space to explore motivations for initiating therapy.
‘A lot of people are taking these medications for non-health related reasons, e.g. if they have a wedding coming up,’ A/Prof Steward said.
‘So it's really worth emphasising that these medications are serious drugs that impact the entire body, and it's not something that should be frivolously taken for the purpose of losing a few kg in a month – only to just have them come back.’
While Prof Collins doesn’t think the BMJ findings should deter prescribing, she said cost must be contextualised early – particularly as maintenance strategies continue to evolve. This may include lower costs associated with food and other medicines.
‘If you're improving your weight-related health, how much would medical visits have cost if your health hadn’t improved?’ she said. ‘These medications are a long-term cost, like a car or a mobile phone. We also don't yet know whether, for some people, they may be able to have periods where they don't take it and then reinitiate at lower doses again.’
With potential PBS listings and new formulations on the horizon, A/Prof Steward said clinical messaging will need to evolve alongside the evidence.
‘Over half a million Australians are now taking these medicines,’ he said. ‘Clinicians want clearer evidence around tapering and maintenance – and right now, they’re operating in the dark.’
For more information, read the AP CPD article Weight loss management.
[post_title] => Are GLP-1 RAs becoming lifelong medicines?
[post_excerpt] => A recent systematic review has reignited debate about what happens when patients stop taking GLP-1 RAs and related incretin therapies.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => are-glp-1-ras-becoming-lifelong-medicines
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-19 15:35:39
[post_modified_gmt] => 2026-01-19 04:35:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31190
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => Are GLP-1 RAs becoming lifelong medicines?
[title] => Are GLP-1 RAs becoming lifelong medicines?
[href] => https://www.australianpharmacist.com.au/are-glp-1-ras-becoming-lifelong-medicines/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31192
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31184
[post_author] => 3410
[post_date] => 2026-01-19 10:54:25
[post_date_gmt] => 2026-01-18 23:54:25
[post_content] => In the Barossa Valley, Travis Schiller FPS shows aged care is about teamwork, trust and better outcomes for residents.
What’s it like working as a pharmacist in the Barossa?
While only an hour or so from the city, the Barossa has all the advantages of a regional location.
It’s a privilege to serve in a community with such a rich history; the people and
the community embrace you and appreciate all you can do for them. When I first moved there, I was very quickly invited to present at service clubs and assist with local health programs.
There’s such a diversity of opportunity and organisations in the area willing
to explore new ways to improve care for the community. I was fortunate to have the support of local residential aged care facilities (RACFs) to explore new ways of supporting their staff and residents and improving medicines-related outcomes.
How did you get your start in aged care?
I developed a passion for it through my honours project on Residential Medication Management Reviews (RMMRs) post-hospital discharge.
I was fortunate to be involved in further projects, and with the support of a local facility, began spending regular time there in 2013.
I was not only interested in the on-site function but how a supply pharmacy and RACF could work together to achieve the best outcomes for residents – where pharmacy staff became part of the team rather than external contractors.
I was also fortunate to be involved in the initial Aged Care On-Site Pharmacist (ACOP) trials, and later assisted in a mentoring program where three privately funded pharmacists worked on site in aged care before the government-funded program rolled out.
Creating a mentoring environment allowed us to combine the benefits of experience in aged care with the enthusiasm, skill and knowledge of the next generation of pharmacists.
Working with independent RACFs meant we could act as the glue that helped them support one another locally, which we facilitated through regional Medication Advisory Committees.
What are the challenges of being embedded in aged care?
The ‘us and them’ mentality I had seen in many sites was the biggest challenge, with rigorous incident reporting leaving supply pharmacies as easy scapegoats.
Reinforcing to facility staff that I was there to assist them, that we were one team, and that our purpose was the residents’ benefit led to a culture shift and better outcomes. Up until the government funded the ACOP measure, funding was always an issue; and the current levels of funded remuneration will continue to be a barrier to the best and brightest taking up and staying in these roles.
What advice do you have for ECPs?
It’s often said that pharmacy is at a crossroads. While this sentiment is generally considered negative, I think it’s a great analogy for the exciting opportunities and options available to those starting out their careers.
There are many roads to travel professionally. When it’s time for a change, take a different route – explore, find what you love and do it. If it doesn’t exist as a career path, create it.
Get involved in the industry through conferences, organisations and networks – and definitely find a mentor, or a few. There are so many great people willing to share their time and knowledge, so don’t be afraid to tap into it.
Where do you see the pharmacy profession evolving?
With increasing role diversity, broader scope and rapid advances in technology, it’s an exciting time to be a pharmacist.
I’d love to see us truly recognised and valued as integral members of the broader healthcare system for all that we do.
I can only see our roles expanding as the population ages, with more specialised positions becoming the norm. Ageing at home will be the next big challenge – and we need to work out how best to support our communities through it.
A day in the life of Travis Schiller FPS, pharmacist owner, Nuriootpa, Barossa Valley, South Australia.
| 7.30 am | Prepare for the day Quick check of emails, paperwork and messages for staffing issues for the day ahead. |
| 8.30 am | Medication advisory meeting Catch up with aged care staff, GPs and the aged care on-site pharmacist. Discuss a recent issue with completing drugs of dependence recording systems and improve procedures to prevent recurrences. Talk about residents removing patches. Also discuss alternate therapies, alternate patch placement and improved surveillance. |
| 10.00 am | In the mall Visit our ‘The Barossa Pharmacist In the Mall’ pharmacy, touch base with rostering coordinator, check in with staff and see if the dispensary needs anything. Check prescriptions in the dispensary and counsel patients. Administer two COVID-19 vaccinations, and consult with other patients on hay fever and skincare treatment options. |
| 12.00 pm | In the main street Visit our nearby sister site, ‘The Barossa Pharmacist In the Main Street’, check with staff and provide lunch cover in the dispensary. Packing client arrives with a change to medicines, so organise the profile change and adjust packs. Warfarin commenced for one of our regulars. Sat with them and discussed the new medicine and their concerns. Receive a prescription for a packing client that doesn’t match profile; phone the GP to clarify. |
| 2.00 pm | Aged care supply and training Assist in the pharmacy with regular daily non-packed aged care orders for the afternoon, checking medication profiles and chart changes from the GP round. Also work through a Certificate III module with a pharmacy assistant after their S2/S3s schedules training. |
| 6.00 pm | Evening meeting Attend the local Health Care Advisory Committee meeting to discuss opportunities to fund facilities for our local hospitals. |
| 7.30 pm | Home time Hopefully make it home in time to say goodnight to my three girls, then relax and review the day with my wife. |
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31175
[post_author] => 235
[post_date] => 2026-01-14 09:29:29
[post_date_gmt] => 2026-01-13 22:29:29
[post_content] => From roles in governance, research and education, hospital pharmacists are practicing to an increasingly advanced scope. But evolving roles must be grounded in clinical need, organisational priorities and demonstrable impact.
At the Alfred Hospital in Melbourne, pharmacists have long practised to an expanded scope. Pharmacy roles include running disease management and anticoagulation services, writing chart corrections in partnership with medical staff and participating in emergency responses such as stroke callouts.
Behind every expanded role is a clear need, said Professor Michael Dooley MPS, Director of Pharmacy at Alfred Health and Chair of PSA’s Hospital Pharmacy Practice Community of Specialty Interest.
‘When you start to think about offering new services or evolving roles, you need to ask why,’ he told attendees at a session on the topic at PSA25 in August. If there isn’t a reason beyond “I’m interested”, then why are you doing it?’
To expand their services, hospital pharmacy departments must also align with organisational and broader governmental priorities, Prof Dooley said.
‘If I want more staff or more support, I need to talk in the language of the organisation and make sure we address issues that are organisational priorities.’
This approach has enabled pharmacists at the Alfred to move beyond dispensary-based roles and embed themselves at key points along the patient journey.
Around 50–60% of pharmacists at the Alfred are allocated to a clinical unit and work as part of the medical team, Prof Dooley explained. A further 20% work in operational roles, such as in sterile suites, dispensaries and outpatients, while around 5% focus on medicines use and safety, and others are in education and training.
‘We don’t centre all our staff in dispensaries,’ Prof Dooley said. ‘The opportunities for people to practise across a whole range of things are really diverse. That happened because we first identified a clinical need and then investigated whether it was within our scope of practice.
‘Anything you’re considering taking forward, you need to think about it in terms of impact.’
Training pathways for hospital pharmacists
For hospital pharmacists looking to expand their scope, there are now multiple pathways available.
‘It used to be said that you had to do your internship at a hospital pharmacy to get in the door,’ said Lauren Foley, Lead Pharmacist for Learning and Development at Alfred Health. ‘But what’s happened over the last 5–10 years is we now have these diverse entry points. It’s about finding the pathway that works for you.’
As well as an internship, pharmacists can undertake foundation residencies, which provide generalist training over a 2-year period.
‘At the 3- to 7-year mark, you can start thinking about specialisation or a registrar training program, which develops advanced practice in a particular area or scope,’ Ms Foley said. ‘There are also external training and credentialing programs.’
Ms Foley highlighted the stroke credentialing program at Alfred Health as an example of expanded practice driven by patient need.
‘It was identified that patients weren’t receiving thrombolysis within the 60-minute timeframe that we know preserves brain function,’ she said. ‘So the question became: how can we improve that outcome?’
One solution was embedding a pharmacist into those stroke teams who see patients in the emergency department. The role of pharmacists was to obtain the best possible medication history, make recommendations around the management of acute blood pressure and facilitate the early administration of thrombolysis.
‘the initiative led to an improvement in the number of patients who received thrombolysis within 60 minutes. That’s how we know the role is making a difference.’
lauren foley
To prepare pharmacists, credentialing requirements include a minimum level of experience, targeted education, assessment, and an objective structured clinical examination with a neurologist and senior pharmacist.
‘We needed to equip pharmacists with the knowledge, the expertise and the confidence to go there and be part of those stroke calls,’ Ms Foley said. ‘It's quite a confronting scenario so you need pharmacists who can make confident and appropriate recommendations in a life-or-death situation.’
Importantly, the impact of the program has been measurable.
‘There has been research showing the initiative led to an improvement in the number of patients who received thrombolysis within 60 minutes,’ Ms Foley said. ‘That’s how we know the role is making a difference.’
Beyond the bedside
The scope of practice for hospital pharmacists goes further than direct patient care. Pharmacists lead medicines safety initiatives, antimicrobial stewardship programs, and research and education programs.
‘There's also an emerging role in hospital pharmacy departments for stewardship pharmacists, who have a particular role or area of interest, and they become the go-to person for specialised advice, whether it be for anticoagulants [or] antibiotics,’ Ms Foley said.
In every role, pharmacists need to work closely with colleagues from other specialties, Prof Dooley said.
‘You need multidisciplinary support. You can't do any of these things by yourself. If you're interested in developing your services, you have to do that as part of the team.’
This is one of Ms Foley’s favourite parts of the job. ‘There are opportunities to have a chat with the physio or the speech pathologist, to ask the dietitian why they’ve recommended a particular type of enteral nutrition, and to be with the doctor on the ward round. It’s so important to learn from people who are specialists in their area.’
Join PSA’s Communities of Specialty Interest to connect, collaborate and advance your specialty practice.
[post_title] => Hospital pharmacists’ scope is expanding
[post_excerpt] => From roles in governance, research and education, hospital pharmacists are practicing to an increasingly advanced scope.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => hospital-pharmacists-scope-is-expanding
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-14 14:06:46
[post_modified_gmt] => 2026-01-14 03:06:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31175
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => Hospital pharmacists’ scope is expanding
[title] => Hospital pharmacists’ scope is expanding
[href] => https://www.australianpharmacist.com.au/hospital-pharmacists-scope-is-expanding/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31179
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31167
[post_author] => 11758
[post_date] => 2026-01-12 13:52:34
[post_date_gmt] => 2026-01-12 02:52:34
[post_content] => PSA’s ASPIRE Palliative Care Foundation Training Program gives pharmacists the skills to deliver this vital care – to patients and families alike.
Australia’s population is living to a greater age, which in turn has led to increased need for end-of-life care. It’s estimated that demand for palliative care in Australia will rise by 50% between now and 2035, and double by 2050.
Until now, most pharmacists have had to navigate complex medication regimes and challenging family conversations – with little to no formal training during university studies.
To help bridge this gap, PSA launched the ASPIRE Palliative Care Foundation Training Program last year. The course, delivered online across eight modules, aims to equip pharmacists with essential, proactive skills – not only for patients, but for the family and carers who also require significant support.
‘The ASPIRE training reminded me that palliative care is not just the last few days of life, it’s actually the weeks, months and sometimes even years after a person has a diagnosis that means that their life is going to be shortened,’ said Amy Gibson MPS, a consultant clinical pharmacist and educator who works as an on-site pharmacist in an Aspect Health aged care facility outside Brisbane.
[caption id="attachment_31171" align="aligncenter" width="500"]
Amy Gibson MPS[/caption]
‘Palliative care is about making plans to keep that patient as comfortable and in the best health possible for the time they’ve got left – often it’s heart failure and chronic lung disease patients.’
A holistic approach
Before completing the ASPIRE training program, Ms Gibson said she ‘didn’t have a lot of skills around palliative care’.
‘I knew about what we refer to as the “Core Four” medicines. I knew about anticipatory prescribing and making sure you’ve got something on hand for pain management, agitation and so on,’ she said.
‘But I hadn’t really thought so much about those social aspects of having conversations with people to find out what actual issues they were having, and how as a pharmacist you could support them.’
While not designed to prepare pharmacists to specialise in palliative care, the ASPIRE training course explores a broad range of topics around end-of-life issues, from symptom management and interdisciplinary palliative care to the role of the pharmacist across everything from medicine management to bereavement and self-care.
The holistic approach of the training resonated with Ms Gibson. ‘There was a lot of psychosocial education, including around what palliative care patients experience and also what that’s like for their families,’ she said. ‘It reinforced cultural perspectives, particularly for [Aboriginal and Torres Strait Islander] peoples, acknowledging that different cultures deal with death and dying in diverse ways and there’s not a one-size-fits-all approach.’
The ASPIRE training puts the carers’ perspectives in place, said Ruilin Ng MPS, a consultant pharmacist and credentialled diabetes educator based in suburban Adelaide. ‘A lot of the time, people are so focused on the person in care that the person around them is not given as much attention.’
The list of drugs a carer picks up can also be a vital clue for pharmacists to open a conversation. ‘A simple, “How are you”, or “How’s it going”, goes a long way,’ she said.
‘Otherwise family members or carers sometimes fall through the cracks. They may not have the support of a counsellor because obviously the focus is not on them.’
The training also reminds pharmacists of their critical role in being proactive around the most fundamental parts of palliative care, Ms Gibson said.
‘There are cases when people have trouble even physically getting to the pharmacy, saying “We need someone to be with Dad 24/7” for example,’ she said. ‘They don’t have the headspace to say that [coming to the pharmacy] isn’t working for them and might not even realise we can arrange delivery, so there’s a lot of emphasis on the practical measures we can provide.’
Medicine management when it’s most critical
As most people aim to spend their final days at home or in an aged care facility rather than in a hospital, the training helps prepare pharmacists to support them, including the specifics of palliative care medicines management.
‘We can assist [prescribers] in knowing what medicines should be prescribed for comfort measures and what medicines should be ceased because they're no longer serving a purpose,’ Ms Gibson said.
This also includes making sure the right medicines are available. ‘If your loved one is in pain or quite agitated, you don’t want to be told you’ve got to wait 24 hours because it’s not in stock,’ Ms Gibson said. ‘The training encourages community pharmacies to have these key palliative [care] medicines on hand so patients’ families don’t have to run around the town trying to find supplies.’
In her aged care role, Ms Gibson works closely with registered nurses to maintain an imprest supply. ‘This is emergency stock, including palliative care medicines, that they might need to use before the next delivery from the pharmacy comes,’ she said.
‘If an after-hours GP comes at night and says, “We need to start this patient on a morphine syringe driver”, we’ve got some ready to go – they don’t have to wait until the order arrives at 3.00 pm the next afternoon. I help the nurses monitor that stock. And if we’re running low, I make sure the order goes through to our supply pharmacy in plenty of time.’
The skills Ms Gibson honed through the ASPIRE training program recently helped her treat a resident with advanced dementia who was admitted to hospital but discharged back to the aged care facility with little warning.
‘She was close to the end of [her] life and they’d ceased everything but the palliative [care] medicines, anticipating she wouldn’t [live] more than a couple of days,’ she said.
‘As soon as I saw the message that she was expected back later that day, I checked that we had enough morphine and midazolam to make sure she could be administered those medicines as soon as she got back, because she was unlikely to be sent back to us with [a supply of] those medications.
‘Her doses were escalating quickly and over the next couple of days I made sure we stayed on top of stock levels, putting orders into the pharmacy regularly to make sure we weren't going to run out overnight.’
The ASPIRE training reinforced the importance of this approach. ‘At the very end of life, the situation can deteriorate quickly, with a change in condition often meaning a change in dose,’ Ms Gibson said.
‘We don’t want people to be uncomfortable and you don’t want to wait a day for the order to arrive. There’s a real need to anticipate what’s going to happen.’
Care after the end
When end of life arrives for the patient, it’s those left behind who need care.
‘The ASPIRE training puts the carer’s perspectives in place, [and] is a very good introduction to the bereavement aspect’ Ms Ng said. ‘[You learn] how to start the conversation, because it’s not an easy topic.’
Pharmacists have an important role in acknowledging carer grief and bereavement after the death of a loved one, and signposting to further support if required.
Keen to learn more about palliative care? Pharmacists, students and interns can enrol free of charge in the Training Plan: ASPIRE Palliative Care Foundation Training Program.
[post_title] => At the end of life, pharmacists are essential
[post_excerpt] => PSA’s ASPIRE Palliative Care Foundation Training Program gives pharmacists the skills to deliver this vital care – to patients and families.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => at-the-end-of-life-pharmacists-are-essential
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-13 09:48:57
[post_modified_gmt] => 2026-01-12 22:48:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31167
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => At the end of life, pharmacists are essential
[title] => At the end of life, pharmacists are essential
[href] => https://www.australianpharmacist.com.au/at-the-end-of-life-pharmacists-are-essential/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31169
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31160
[post_author] => 11750
[post_date] => 2026-01-12 11:56:10
[post_date_gmt] => 2026-01-12 00:56:10
[post_content] => Compounding environments must be designed to minimise contamination risk – including keeping meal breaks well away from the bench.
For most, the image of a typical ‘behind the counter’ pharmacy environment is not one of expansive space. Instead, it’s a compact and busy environment where almost every inch is occupied by something essential for us to do our job. There’s the dispensary itself, an area where medicines are compounded, and usually, another space for staff to take their well-deserved lunch break, too.
Separation of compounding and lunch areas is essential, not only for keeping crumbs out of capsules, but to ensure compounded medicines are free from contamination, consistently meet quality standards and for maintaining the safety of staff.1,2
Why is it important?
Pharmacists have a legal and professional responsibility to ensure compounding occurs in an environment that has been adequately designed, equipped and resourced.2
Compounding practices should be informed by relevant guidelines and standards for Good Manufacturing Practice (GMP), which reinforce the importance of prohibiting food and drink in compounding areas.2,3 These areas need to be clean and orderly to protect ingredients and compounded medicines from microbial and particulate contamination, throughout all stages of compounding.3 Grabbing a quick bite between batches could put medicine quality, staff and patient safety at risk.
How should a compounding area be organised?
Requirements vary across pharmacy premises depending on the complexity of the compounding being conducted. Facilities and equipment must comply with relevant Commonwealth and state or territory legislation, relevant regulatory authority requirements and Australian standards.4
Some key considerations for compounding areas include that4,5:
Complex compounding activities will require more specialised facilities and equipment.4 Non-sterile complex compounding should ideally occur in a dedicated laboratory separated from other parts of the pharmacy by floor-to-ceiling walls, with a door for entry and exit.4 It’s important to remember that if the laboratory is accessible by the public, the door should be lockable.4
Risk assessments are useful tools to determine whether compounding areas and equipment are suitable and safe for the medicines being compounded.2 If an issue is identified, remember it’s important to bring this to the attention of the person responsible for the premises, to allow for corrective actions to be implemented.
See the Australian Pharmaceutical Formulary (APF) Compounding decision support and risk assessment tool for guidance.
Everyone is entitled to a lunch break. Designating a separate space for meals away from compounding areas reduces contamination risk and maintains GMP standards for compounded medicines, staff and patients.
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31190
[post_author] => 3410
[post_date] => 2026-01-19 11:11:00
[post_date_gmt] => 2026-01-19 00:11:00
[post_content] => A recent systematic review published in the BMJ has reignited debate about what happens when patients stop taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related GLP-1–based incretin therapies.
The analysis found that weight often returns quickly once treatment is discontinued – in some cases faster than with other weight-loss interventions.
And it’s not just weight that rebounds. Cardiometabolic risk markers, including blood pressure, blood glucose and blood lipids, were also found to revert towards pre-treatment levels.
As prescribing of these medicines continues to rise, the findings raise a broader question: should patients be starting these medicines in the first place?
AP spoke with experts to unpack the evidence.
Weight regain predictable, but not the real problem
Professor Clare Collins, Professor of Nutrition and Dietetics at the University of Newcastle, said the pattern of rapid weight regain following cessation was entirely unsurprising.
‘This is exactly what you would expect,’ she said.
[caption id="attachment_31196" align="aligncenter" width="400"]
Professor Clare Collins[/caption]
For Prof Collins, the findings reinforce a core principle of chronic disease management: when an effective treatment is withdrawn, the condition it was controlling usually returns.
‘If someone stops taking antihypertensives, what happens? Their blood pressure goes back up,’ she said.
‘While predictable, the deterioration back to baseline is why we need to be thinking much more carefully about what is needed for long-term maintenance.'
Prof clare collins
While weight regain attracts headlines, Prof Collins said the more clinically concerning signal is the deterioration in metabolic markers once treatment ceases.
‘While predictable, the deterioration back to baseline is why we need to be thinking much more carefully about what is needed for long-term maintenance.’
Not a sign of treatment failure
Associate Professor Trevor Steward, Director of the Melbourne School of Psychological Sciences’ Brain and Mental Health Hub, agrees that the rebound effect reflects how GLP-1 RA medicines work, rather than a failure of the drugs or patient behaviour.
Instead of creating permanent physiological change, GLP-1 RAs amplify hormonal signals that already exist in the body – particularly those involved in appetite regulation, digestion and satiety. The benefits seen during treatment depend on sustained exposure to these hormones.
[caption id="attachment_31197" align="aligncenter" width="400"]
Associate Professor Trevor Steward[/caption]
‘That's why we see this rapid rebound effect of people experiencing weight gain when they stop using them, because there’s no longer increased circulating levels of hormones impacting their different body systems,’ A/Prof Steward said.
However, the mechanisms behind the accelerated regain are not yet fully understood.
‘Some indications are that while these newer medications help people lose weight faster, they may cause a stronger slingshot effect,’ he said.
Prof Collins points to emerging evidence suggesting incretin therapies cross the blood–brain barrier, influencing reward pathways linked to appetite and environmental cues to eat.
‘For example, if you go to the supermarket for a loaf of bread and come back with donuts too – that’s what’s referred to as “food noise”,’ she said. ‘Some people say this [noise] really goes down when using these therapies.’
When treatment is withdrawn, the surrounding food environment can quickly reassert itself. This is where tapering, behavioural support and nutrition strategies become critical.
‘It may be that people are more receptive to maintenance support programs as they’re tapering or finding out what their maintenance medication dose is,’ she said. ‘If they’re aware of that point, they’ll recognise when the food noise starts again.’
Nutrition: the missing variable
Prof Collins recently led a systematic review which highlighted that changes in dietary intake and nutrition remain largely invisible in incretin trials.
‘Of all the phase three trials, only two actually measured and reported what people ate,’ she said.
Most trials provided standardised advice but did not collect data on dietary intake, leaving clinicians to infer how appetite suppression, nausea and early satiety shaped eating patterns over time.
‘They mostly worked with people to identify dietary changes that would remove about 2,000 kilojoules a day – enough to trigger weight loss,’ she said.
But reduced intake doesn’t automatically equate to improved diet quality or nutrient adequacy, with micronutrient deficiencies and loss of lean mass emerging if nutrition isn’t actively monitored.
With frequent patient contact, Prof Collins believes pharmacists are uniquely placed to identify emerging problems, intervene early and support appropriate referral to dietitians for medical nutrition therapy.
‘[And] if pharmacy staff are trained, they can say, “Hang on a minute, you need to talk to the pharmacist”.’
The University of Newcastle also has a suite of resources pharmacists could direct patients to, including a healthy eating quiz and obesity management podcast, available here.
When visible deterioration or rapid weight loss appears, referral becomes essential. ‘Once you think, “this person is fading before our eyes”, that’s when you alert the GP and refer to a dietitian,’ Prof Collins said.
Supporting persistence with therapy also plays a role in outcomes.
‘The main benefit isn’t weight – it’s metabolic health,’ she said. ‘Helping people manage [adverse] effects supports continuation.’
As weight loss occurs, pharmacists should also be alert to the need to review other medicines.
‘If someone is dropping weight rapidly, blood sugars and blood pressure can fall,’ she said. ‘There are also rare but potentially severe complications – pancreatitis, gallstones, bowel obstruction and non-arteritic anterior ischaemic optic neuropathy,’ she said. ‘Staying well hydrated is critical – urine should look straw-coloured.’
Playing the long game
A/Prof Steward said there’s now sufficient evidence to normalise weight regain after cessation. And given the established risks associated with long-term obesity, he suggests continued therapy may represent a lower-risk option for some patients.
‘As we know, having a very high BMI for a long period of time confers its own levels of risks in terms of cardiovascular disease and other issues,’ he said. ‘So [many clinicians] think it's worth staying on these [medicines] long term as opposed to the potential risk of weight [regain].’
For people with repeated cycles of weight loss and regain, A/Prof Steward said GLP-1 RAs are increasingly being understood as potentially lifelong treatments – similar to medicines used for other chronic conditions.
‘Clinicians want clearer evidence around tapering and maintenance – and right now, they’re operating in the dark.'
A/prof trevor steward
‘I recently had a conversation with someone who has lost over 50 kilograms three times in her life,’ he said. ‘After a sustained period of lifestyle change, the weight still comes back. She would rather stay on these medicines for life than put her body through that cycle again.’
As use expands, A/Prof Steward emphasised the importance of clarifying intent and expectations before treatment begins.
‘It's really important to have that conversation with a pharmacist or GP about whether they want to make that commitment to potentially taking these long term,’ he said.
This also creates space to explore motivations for initiating therapy.
‘A lot of people are taking these medications for non-health related reasons, e.g. if they have a wedding coming up,’ A/Prof Steward said.
‘So it's really worth emphasising that these medications are serious drugs that impact the entire body, and it's not something that should be frivolously taken for the purpose of losing a few kg in a month – only to just have them come back.’
While Prof Collins doesn’t think the BMJ findings should deter prescribing, she said cost must be contextualised early – particularly as maintenance strategies continue to evolve. This may include lower costs associated with food and other medicines.
‘If you're improving your weight-related health, how much would medical visits have cost if your health hadn’t improved?’ she said. ‘These medications are a long-term cost, like a car or a mobile phone. We also don't yet know whether, for some people, they may be able to have periods where they don't take it and then reinitiate at lower doses again.’
With potential PBS listings and new formulations on the horizon, A/Prof Steward said clinical messaging will need to evolve alongside the evidence.
‘Over half a million Australians are now taking these medicines,’ he said. ‘Clinicians want clearer evidence around tapering and maintenance – and right now, they’re operating in the dark.’
For more information, read the AP CPD article Weight loss management.
[post_title] => Are GLP-1 RAs becoming lifelong medicines?
[post_excerpt] => A recent systematic review has reignited debate about what happens when patients stop taking GLP-1 RAs and related incretin therapies.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => are-glp-1-ras-becoming-lifelong-medicines
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-19 15:35:39
[post_modified_gmt] => 2026-01-19 04:35:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31190
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => Are GLP-1 RAs becoming lifelong medicines?
[title] => Are GLP-1 RAs becoming lifelong medicines?
[href] => https://www.australianpharmacist.com.au/are-glp-1-ras-becoming-lifelong-medicines/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31192
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31184
[post_author] => 3410
[post_date] => 2026-01-19 10:54:25
[post_date_gmt] => 2026-01-18 23:54:25
[post_content] => In the Barossa Valley, Travis Schiller FPS shows aged care is about teamwork, trust and better outcomes for residents.
What’s it like working as a pharmacist in the Barossa?
While only an hour or so from the city, the Barossa has all the advantages of a regional location.
It’s a privilege to serve in a community with such a rich history; the people and
the community embrace you and appreciate all you can do for them. When I first moved there, I was very quickly invited to present at service clubs and assist with local health programs.
There’s such a diversity of opportunity and organisations in the area willing
to explore new ways to improve care for the community. I was fortunate to have the support of local residential aged care facilities (RACFs) to explore new ways of supporting their staff and residents and improving medicines-related outcomes.
How did you get your start in aged care?
I developed a passion for it through my honours project on Residential Medication Management Reviews (RMMRs) post-hospital discharge.
I was fortunate to be involved in further projects, and with the support of a local facility, began spending regular time there in 2013.
I was not only interested in the on-site function but how a supply pharmacy and RACF could work together to achieve the best outcomes for residents – where pharmacy staff became part of the team rather than external contractors.
I was also fortunate to be involved in the initial Aged Care On-Site Pharmacist (ACOP) trials, and later assisted in a mentoring program where three privately funded pharmacists worked on site in aged care before the government-funded program rolled out.
Creating a mentoring environment allowed us to combine the benefits of experience in aged care with the enthusiasm, skill and knowledge of the next generation of pharmacists.
Working with independent RACFs meant we could act as the glue that helped them support one another locally, which we facilitated through regional Medication Advisory Committees.
What are the challenges of being embedded in aged care?
The ‘us and them’ mentality I had seen in many sites was the biggest challenge, with rigorous incident reporting leaving supply pharmacies as easy scapegoats.
Reinforcing to facility staff that I was there to assist them, that we were one team, and that our purpose was the residents’ benefit led to a culture shift and better outcomes. Up until the government funded the ACOP measure, funding was always an issue; and the current levels of funded remuneration will continue to be a barrier to the best and brightest taking up and staying in these roles.
What advice do you have for ECPs?
It’s often said that pharmacy is at a crossroads. While this sentiment is generally considered negative, I think it’s a great analogy for the exciting opportunities and options available to those starting out their careers.
There are many roads to travel professionally. When it’s time for a change, take a different route – explore, find what you love and do it. If it doesn’t exist as a career path, create it.
Get involved in the industry through conferences, organisations and networks – and definitely find a mentor, or a few. There are so many great people willing to share their time and knowledge, so don’t be afraid to tap into it.
Where do you see the pharmacy profession evolving?
With increasing role diversity, broader scope and rapid advances in technology, it’s an exciting time to be a pharmacist.
I’d love to see us truly recognised and valued as integral members of the broader healthcare system for all that we do.
I can only see our roles expanding as the population ages, with more specialised positions becoming the norm. Ageing at home will be the next big challenge – and we need to work out how best to support our communities through it.
A day in the life of Travis Schiller FPS, pharmacist owner, Nuriootpa, Barossa Valley, South Australia.
| 7.30 am | Prepare for the day Quick check of emails, paperwork and messages for staffing issues for the day ahead. |
| 8.30 am | Medication advisory meeting Catch up with aged care staff, GPs and the aged care on-site pharmacist. Discuss a recent issue with completing drugs of dependence recording systems and improve procedures to prevent recurrences. Talk about residents removing patches. Also discuss alternate therapies, alternate patch placement and improved surveillance. |
| 10.00 am | In the mall Visit our ‘The Barossa Pharmacist In the Mall’ pharmacy, touch base with rostering coordinator, check in with staff and see if the dispensary needs anything. Check prescriptions in the dispensary and counsel patients. Administer two COVID-19 vaccinations, and consult with other patients on hay fever and skincare treatment options. |
| 12.00 pm | In the main street Visit our nearby sister site, ‘The Barossa Pharmacist In the Main Street’, check with staff and provide lunch cover in the dispensary. Packing client arrives with a change to medicines, so organise the profile change and adjust packs. Warfarin commenced for one of our regulars. Sat with them and discussed the new medicine and their concerns. Receive a prescription for a packing client that doesn’t match profile; phone the GP to clarify. |
| 2.00 pm | Aged care supply and training Assist in the pharmacy with regular daily non-packed aged care orders for the afternoon, checking medication profiles and chart changes from the GP round. Also work through a Certificate III module with a pharmacy assistant after their S2/S3s schedules training. |
| 6.00 pm | Evening meeting Attend the local Health Care Advisory Committee meeting to discuss opportunities to fund facilities for our local hospitals. |
| 7.30 pm | Home time Hopefully make it home in time to say goodnight to my three girls, then relax and review the day with my wife. |
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31175
[post_author] => 235
[post_date] => 2026-01-14 09:29:29
[post_date_gmt] => 2026-01-13 22:29:29
[post_content] => From roles in governance, research and education, hospital pharmacists are practicing to an increasingly advanced scope. But evolving roles must be grounded in clinical need, organisational priorities and demonstrable impact.
At the Alfred Hospital in Melbourne, pharmacists have long practised to an expanded scope. Pharmacy roles include running disease management and anticoagulation services, writing chart corrections in partnership with medical staff and participating in emergency responses such as stroke callouts.
Behind every expanded role is a clear need, said Professor Michael Dooley MPS, Director of Pharmacy at Alfred Health and Chair of PSA’s Hospital Pharmacy Practice Community of Specialty Interest.
‘When you start to think about offering new services or evolving roles, you need to ask why,’ he told attendees at a session on the topic at PSA25 in August. If there isn’t a reason beyond “I’m interested”, then why are you doing it?’
To expand their services, hospital pharmacy departments must also align with organisational and broader governmental priorities, Prof Dooley said.
‘If I want more staff or more support, I need to talk in the language of the organisation and make sure we address issues that are organisational priorities.’
This approach has enabled pharmacists at the Alfred to move beyond dispensary-based roles and embed themselves at key points along the patient journey.
Around 50–60% of pharmacists at the Alfred are allocated to a clinical unit and work as part of the medical team, Prof Dooley explained. A further 20% work in operational roles, such as in sterile suites, dispensaries and outpatients, while around 5% focus on medicines use and safety, and others are in education and training.
‘We don’t centre all our staff in dispensaries,’ Prof Dooley said. ‘The opportunities for people to practise across a whole range of things are really diverse. That happened because we first identified a clinical need and then investigated whether it was within our scope of practice.
‘Anything you’re considering taking forward, you need to think about it in terms of impact.’
Training pathways for hospital pharmacists
For hospital pharmacists looking to expand their scope, there are now multiple pathways available.
‘It used to be said that you had to do your internship at a hospital pharmacy to get in the door,’ said Lauren Foley, Lead Pharmacist for Learning and Development at Alfred Health. ‘But what’s happened over the last 5–10 years is we now have these diverse entry points. It’s about finding the pathway that works for you.’
As well as an internship, pharmacists can undertake foundation residencies, which provide generalist training over a 2-year period.
‘At the 3- to 7-year mark, you can start thinking about specialisation or a registrar training program, which develops advanced practice in a particular area or scope,’ Ms Foley said. ‘There are also external training and credentialing programs.’
Ms Foley highlighted the stroke credentialing program at Alfred Health as an example of expanded practice driven by patient need.
‘It was identified that patients weren’t receiving thrombolysis within the 60-minute timeframe that we know preserves brain function,’ she said. ‘So the question became: how can we improve that outcome?’
One solution was embedding a pharmacist into those stroke teams who see patients in the emergency department. The role of pharmacists was to obtain the best possible medication history, make recommendations around the management of acute blood pressure and facilitate the early administration of thrombolysis.
‘the initiative led to an improvement in the number of patients who received thrombolysis within 60 minutes. That’s how we know the role is making a difference.’
lauren foley
To prepare pharmacists, credentialing requirements include a minimum level of experience, targeted education, assessment, and an objective structured clinical examination with a neurologist and senior pharmacist.
‘We needed to equip pharmacists with the knowledge, the expertise and the confidence to go there and be part of those stroke calls,’ Ms Foley said. ‘It's quite a confronting scenario so you need pharmacists who can make confident and appropriate recommendations in a life-or-death situation.’
Importantly, the impact of the program has been measurable.
‘There has been research showing the initiative led to an improvement in the number of patients who received thrombolysis within 60 minutes,’ Ms Foley said. ‘That’s how we know the role is making a difference.’
Beyond the bedside
The scope of practice for hospital pharmacists goes further than direct patient care. Pharmacists lead medicines safety initiatives, antimicrobial stewardship programs, and research and education programs.
‘There's also an emerging role in hospital pharmacy departments for stewardship pharmacists, who have a particular role or area of interest, and they become the go-to person for specialised advice, whether it be for anticoagulants [or] antibiotics,’ Ms Foley said.
In every role, pharmacists need to work closely with colleagues from other specialties, Prof Dooley said.
‘You need multidisciplinary support. You can't do any of these things by yourself. If you're interested in developing your services, you have to do that as part of the team.’
This is one of Ms Foley’s favourite parts of the job. ‘There are opportunities to have a chat with the physio or the speech pathologist, to ask the dietitian why they’ve recommended a particular type of enteral nutrition, and to be with the doctor on the ward round. It’s so important to learn from people who are specialists in their area.’
Join PSA’s Communities of Specialty Interest to connect, collaborate and advance your specialty practice.
[post_title] => Hospital pharmacists’ scope is expanding
[post_excerpt] => From roles in governance, research and education, hospital pharmacists are practicing to an increasingly advanced scope.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => hospital-pharmacists-scope-is-expanding
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-14 14:06:46
[post_modified_gmt] => 2026-01-14 03:06:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31175
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => Hospital pharmacists’ scope is expanding
[title] => Hospital pharmacists’ scope is expanding
[href] => https://www.australianpharmacist.com.au/hospital-pharmacists-scope-is-expanding/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31179
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31167
[post_author] => 11758
[post_date] => 2026-01-12 13:52:34
[post_date_gmt] => 2026-01-12 02:52:34
[post_content] => PSA’s ASPIRE Palliative Care Foundation Training Program gives pharmacists the skills to deliver this vital care – to patients and families alike.
Australia’s population is living to a greater age, which in turn has led to increased need for end-of-life care. It’s estimated that demand for palliative care in Australia will rise by 50% between now and 2035, and double by 2050.
Until now, most pharmacists have had to navigate complex medication regimes and challenging family conversations – with little to no formal training during university studies.
To help bridge this gap, PSA launched the ASPIRE Palliative Care Foundation Training Program last year. The course, delivered online across eight modules, aims to equip pharmacists with essential, proactive skills – not only for patients, but for the family and carers who also require significant support.
‘The ASPIRE training reminded me that palliative care is not just the last few days of life, it’s actually the weeks, months and sometimes even years after a person has a diagnosis that means that their life is going to be shortened,’ said Amy Gibson MPS, a consultant clinical pharmacist and educator who works as an on-site pharmacist in an Aspect Health aged care facility outside Brisbane.
[caption id="attachment_31171" align="aligncenter" width="500"]
Amy Gibson MPS[/caption]
‘Palliative care is about making plans to keep that patient as comfortable and in the best health possible for the time they’ve got left – often it’s heart failure and chronic lung disease patients.’
A holistic approach
Before completing the ASPIRE training program, Ms Gibson said she ‘didn’t have a lot of skills around palliative care’.
‘I knew about what we refer to as the “Core Four” medicines. I knew about anticipatory prescribing and making sure you’ve got something on hand for pain management, agitation and so on,’ she said.
‘But I hadn’t really thought so much about those social aspects of having conversations with people to find out what actual issues they were having, and how as a pharmacist you could support them.’
While not designed to prepare pharmacists to specialise in palliative care, the ASPIRE training course explores a broad range of topics around end-of-life issues, from symptom management and interdisciplinary palliative care to the role of the pharmacist across everything from medicine management to bereavement and self-care.
The holistic approach of the training resonated with Ms Gibson. ‘There was a lot of psychosocial education, including around what palliative care patients experience and also what that’s like for their families,’ she said. ‘It reinforced cultural perspectives, particularly for [Aboriginal and Torres Strait Islander] peoples, acknowledging that different cultures deal with death and dying in diverse ways and there’s not a one-size-fits-all approach.’
The ASPIRE training puts the carers’ perspectives in place, said Ruilin Ng MPS, a consultant pharmacist and credentialled diabetes educator based in suburban Adelaide. ‘A lot of the time, people are so focused on the person in care that the person around them is not given as much attention.’
The list of drugs a carer picks up can also be a vital clue for pharmacists to open a conversation. ‘A simple, “How are you”, or “How’s it going”, goes a long way,’ she said.
‘Otherwise family members or carers sometimes fall through the cracks. They may not have the support of a counsellor because obviously the focus is not on them.’
The training also reminds pharmacists of their critical role in being proactive around the most fundamental parts of palliative care, Ms Gibson said.
‘There are cases when people have trouble even physically getting to the pharmacy, saying “We need someone to be with Dad 24/7” for example,’ she said. ‘They don’t have the headspace to say that [coming to the pharmacy] isn’t working for them and might not even realise we can arrange delivery, so there’s a lot of emphasis on the practical measures we can provide.’
Medicine management when it’s most critical
As most people aim to spend their final days at home or in an aged care facility rather than in a hospital, the training helps prepare pharmacists to support them, including the specifics of palliative care medicines management.
‘We can assist [prescribers] in knowing what medicines should be prescribed for comfort measures and what medicines should be ceased because they're no longer serving a purpose,’ Ms Gibson said.
This also includes making sure the right medicines are available. ‘If your loved one is in pain or quite agitated, you don’t want to be told you’ve got to wait 24 hours because it’s not in stock,’ Ms Gibson said. ‘The training encourages community pharmacies to have these key palliative [care] medicines on hand so patients’ families don’t have to run around the town trying to find supplies.’
In her aged care role, Ms Gibson works closely with registered nurses to maintain an imprest supply. ‘This is emergency stock, including palliative care medicines, that they might need to use before the next delivery from the pharmacy comes,’ she said.
‘If an after-hours GP comes at night and says, “We need to start this patient on a morphine syringe driver”, we’ve got some ready to go – they don’t have to wait until the order arrives at 3.00 pm the next afternoon. I help the nurses monitor that stock. And if we’re running low, I make sure the order goes through to our supply pharmacy in plenty of time.’
The skills Ms Gibson honed through the ASPIRE training program recently helped her treat a resident with advanced dementia who was admitted to hospital but discharged back to the aged care facility with little warning.
‘She was close to the end of [her] life and they’d ceased everything but the palliative [care] medicines, anticipating she wouldn’t [live] more than a couple of days,’ she said.
‘As soon as I saw the message that she was expected back later that day, I checked that we had enough morphine and midazolam to make sure she could be administered those medicines as soon as she got back, because she was unlikely to be sent back to us with [a supply of] those medications.
‘Her doses were escalating quickly and over the next couple of days I made sure we stayed on top of stock levels, putting orders into the pharmacy regularly to make sure we weren't going to run out overnight.’
The ASPIRE training reinforced the importance of this approach. ‘At the very end of life, the situation can deteriorate quickly, with a change in condition often meaning a change in dose,’ Ms Gibson said.
‘We don’t want people to be uncomfortable and you don’t want to wait a day for the order to arrive. There’s a real need to anticipate what’s going to happen.’
Care after the end
When end of life arrives for the patient, it’s those left behind who need care.
‘The ASPIRE training puts the carer’s perspectives in place, [and] is a very good introduction to the bereavement aspect’ Ms Ng said. ‘[You learn] how to start the conversation, because it’s not an easy topic.’
Pharmacists have an important role in acknowledging carer grief and bereavement after the death of a loved one, and signposting to further support if required.
Keen to learn more about palliative care? Pharmacists, students and interns can enrol free of charge in the Training Plan: ASPIRE Palliative Care Foundation Training Program.
[post_title] => At the end of life, pharmacists are essential
[post_excerpt] => PSA’s ASPIRE Palliative Care Foundation Training Program gives pharmacists the skills to deliver this vital care – to patients and families.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => at-the-end-of-life-pharmacists-are-essential
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-13 09:48:57
[post_modified_gmt] => 2026-01-12 22:48:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31167
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => At the end of life, pharmacists are essential
[title] => At the end of life, pharmacists are essential
[href] => https://www.australianpharmacist.com.au/at-the-end-of-life-pharmacists-are-essential/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31169
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31160
[post_author] => 11750
[post_date] => 2026-01-12 11:56:10
[post_date_gmt] => 2026-01-12 00:56:10
[post_content] => Compounding environments must be designed to minimise contamination risk – including keeping meal breaks well away from the bench.
For most, the image of a typical ‘behind the counter’ pharmacy environment is not one of expansive space. Instead, it’s a compact and busy environment where almost every inch is occupied by something essential for us to do our job. There’s the dispensary itself, an area where medicines are compounded, and usually, another space for staff to take their well-deserved lunch break, too.
Separation of compounding and lunch areas is essential, not only for keeping crumbs out of capsules, but to ensure compounded medicines are free from contamination, consistently meet quality standards and for maintaining the safety of staff.1,2
Why is it important?
Pharmacists have a legal and professional responsibility to ensure compounding occurs in an environment that has been adequately designed, equipped and resourced.2
Compounding practices should be informed by relevant guidelines and standards for Good Manufacturing Practice (GMP), which reinforce the importance of prohibiting food and drink in compounding areas.2,3 These areas need to be clean and orderly to protect ingredients and compounded medicines from microbial and particulate contamination, throughout all stages of compounding.3 Grabbing a quick bite between batches could put medicine quality, staff and patient safety at risk.
How should a compounding area be organised?
Requirements vary across pharmacy premises depending on the complexity of the compounding being conducted. Facilities and equipment must comply with relevant Commonwealth and state or territory legislation, relevant regulatory authority requirements and Australian standards.4
Some key considerations for compounding areas include that4,5:
Complex compounding activities will require more specialised facilities and equipment.4 Non-sterile complex compounding should ideally occur in a dedicated laboratory separated from other parts of the pharmacy by floor-to-ceiling walls, with a door for entry and exit.4 It’s important to remember that if the laboratory is accessible by the public, the door should be lockable.4
Risk assessments are useful tools to determine whether compounding areas and equipment are suitable and safe for the medicines being compounded.2 If an issue is identified, remember it’s important to bring this to the attention of the person responsible for the premises, to allow for corrective actions to be implemented.
See the Australian Pharmaceutical Formulary (APF) Compounding decision support and risk assessment tool for guidance.
Everyone is entitled to a lunch break. Designating a separate space for meals away from compounding areas reduces contamination risk and maintains GMP standards for compounded medicines, staff and patients.
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31190
[post_author] => 3410
[post_date] => 2026-01-19 11:11:00
[post_date_gmt] => 2026-01-19 00:11:00
[post_content] => A recent systematic review published in the BMJ has reignited debate about what happens when patients stop taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related GLP-1–based incretin therapies.
The analysis found that weight often returns quickly once treatment is discontinued – in some cases faster than with other weight-loss interventions.
And it’s not just weight that rebounds. Cardiometabolic risk markers, including blood pressure, blood glucose and blood lipids, were also found to revert towards pre-treatment levels.
As prescribing of these medicines continues to rise, the findings raise a broader question: should patients be starting these medicines in the first place?
AP spoke with experts to unpack the evidence.
Weight regain predictable, but not the real problem
Professor Clare Collins, Professor of Nutrition and Dietetics at the University of Newcastle, said the pattern of rapid weight regain following cessation was entirely unsurprising.
‘This is exactly what you would expect,’ she said.
[caption id="attachment_31196" align="aligncenter" width="400"]
Professor Clare Collins[/caption]
For Prof Collins, the findings reinforce a core principle of chronic disease management: when an effective treatment is withdrawn, the condition it was controlling usually returns.
‘If someone stops taking antihypertensives, what happens? Their blood pressure goes back up,’ she said.
‘While predictable, the deterioration back to baseline is why we need to be thinking much more carefully about what is needed for long-term maintenance.'
Prof clare collins
While weight regain attracts headlines, Prof Collins said the more clinically concerning signal is the deterioration in metabolic markers once treatment ceases.
‘While predictable, the deterioration back to baseline is why we need to be thinking much more carefully about what is needed for long-term maintenance.’
Not a sign of treatment failure
Associate Professor Trevor Steward, Director of the Melbourne School of Psychological Sciences’ Brain and Mental Health Hub, agrees that the rebound effect reflects how GLP-1 RA medicines work, rather than a failure of the drugs or patient behaviour.
Instead of creating permanent physiological change, GLP-1 RAs amplify hormonal signals that already exist in the body – particularly those involved in appetite regulation, digestion and satiety. The benefits seen during treatment depend on sustained exposure to these hormones.
[caption id="attachment_31197" align="aligncenter" width="400"]
Associate Professor Trevor Steward[/caption]
‘That's why we see this rapid rebound effect of people experiencing weight gain when they stop using them, because there’s no longer increased circulating levels of hormones impacting their different body systems,’ A/Prof Steward said.
However, the mechanisms behind the accelerated regain are not yet fully understood.
‘Some indications are that while these newer medications help people lose weight faster, they may cause a stronger slingshot effect,’ he said.
Prof Collins points to emerging evidence suggesting incretin therapies cross the blood–brain barrier, influencing reward pathways linked to appetite and environmental cues to eat.
‘For example, if you go to the supermarket for a loaf of bread and come back with donuts too – that’s what’s referred to as “food noise”,’ she said. ‘Some people say this [noise] really goes down when using these therapies.’
When treatment is withdrawn, the surrounding food environment can quickly reassert itself. This is where tapering, behavioural support and nutrition strategies become critical.
‘It may be that people are more receptive to maintenance support programs as they’re tapering or finding out what their maintenance medication dose is,’ she said. ‘If they’re aware of that point, they’ll recognise when the food noise starts again.’
Nutrition: the missing variable
Prof Collins recently led a systematic review which highlighted that changes in dietary intake and nutrition remain largely invisible in incretin trials.
‘Of all the phase three trials, only two actually measured and reported what people ate,’ she said.
Most trials provided standardised advice but did not collect data on dietary intake, leaving clinicians to infer how appetite suppression, nausea and early satiety shaped eating patterns over time.
‘They mostly worked with people to identify dietary changes that would remove about 2,000 kilojoules a day – enough to trigger weight loss,’ she said.
But reduced intake doesn’t automatically equate to improved diet quality or nutrient adequacy, with micronutrient deficiencies and loss of lean mass emerging if nutrition isn’t actively monitored.
With frequent patient contact, Prof Collins believes pharmacists are uniquely placed to identify emerging problems, intervene early and support appropriate referral to dietitians for medical nutrition therapy.
‘[And] if pharmacy staff are trained, they can say, “Hang on a minute, you need to talk to the pharmacist”.’
The University of Newcastle also has a suite of resources pharmacists could direct patients to, including a healthy eating quiz and obesity management podcast, available here.
When visible deterioration or rapid weight loss appears, referral becomes essential. ‘Once you think, “this person is fading before our eyes”, that’s when you alert the GP and refer to a dietitian,’ Prof Collins said.
Supporting persistence with therapy also plays a role in outcomes.
‘The main benefit isn’t weight – it’s metabolic health,’ she said. ‘Helping people manage [adverse] effects supports continuation.’
As weight loss occurs, pharmacists should also be alert to the need to review other medicines.
‘If someone is dropping weight rapidly, blood sugars and blood pressure can fall,’ she said. ‘There are also rare but potentially severe complications – pancreatitis, gallstones, bowel obstruction and non-arteritic anterior ischaemic optic neuropathy,’ she said. ‘Staying well hydrated is critical – urine should look straw-coloured.’
Playing the long game
A/Prof Steward said there’s now sufficient evidence to normalise weight regain after cessation. And given the established risks associated with long-term obesity, he suggests continued therapy may represent a lower-risk option for some patients.
‘As we know, having a very high BMI for a long period of time confers its own levels of risks in terms of cardiovascular disease and other issues,’ he said. ‘So [many clinicians] think it's worth staying on these [medicines] long term as opposed to the potential risk of weight [regain].’
For people with repeated cycles of weight loss and regain, A/Prof Steward said GLP-1 RAs are increasingly being understood as potentially lifelong treatments – similar to medicines used for other chronic conditions.
‘Clinicians want clearer evidence around tapering and maintenance – and right now, they’re operating in the dark.'
A/prof trevor steward
‘I recently had a conversation with someone who has lost over 50 kilograms three times in her life,’ he said. ‘After a sustained period of lifestyle change, the weight still comes back. She would rather stay on these medicines for life than put her body through that cycle again.’
As use expands, A/Prof Steward emphasised the importance of clarifying intent and expectations before treatment begins.
‘It's really important to have that conversation with a pharmacist or GP about whether they want to make that commitment to potentially taking these long term,’ he said.
This also creates space to explore motivations for initiating therapy.
‘A lot of people are taking these medications for non-health related reasons, e.g. if they have a wedding coming up,’ A/Prof Steward said.
‘So it's really worth emphasising that these medications are serious drugs that impact the entire body, and it's not something that should be frivolously taken for the purpose of losing a few kg in a month – only to just have them come back.’
While Prof Collins doesn’t think the BMJ findings should deter prescribing, she said cost must be contextualised early – particularly as maintenance strategies continue to evolve. This may include lower costs associated with food and other medicines.
‘If you're improving your weight-related health, how much would medical visits have cost if your health hadn’t improved?’ she said. ‘These medications are a long-term cost, like a car or a mobile phone. We also don't yet know whether, for some people, they may be able to have periods where they don't take it and then reinitiate at lower doses again.’
With potential PBS listings and new formulations on the horizon, A/Prof Steward said clinical messaging will need to evolve alongside the evidence.
‘Over half a million Australians are now taking these medicines,’ he said. ‘Clinicians want clearer evidence around tapering and maintenance – and right now, they’re operating in the dark.’
For more information, read the AP CPD article Weight loss management.
[post_title] => Are GLP-1 RAs becoming lifelong medicines?
[post_excerpt] => A recent systematic review has reignited debate about what happens when patients stop taking GLP-1 RAs and related incretin therapies.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => are-glp-1-ras-becoming-lifelong-medicines
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-19 15:35:39
[post_modified_gmt] => 2026-01-19 04:35:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31190
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => Are GLP-1 RAs becoming lifelong medicines?
[title] => Are GLP-1 RAs becoming lifelong medicines?
[href] => https://www.australianpharmacist.com.au/are-glp-1-ras-becoming-lifelong-medicines/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31192
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31184
[post_author] => 3410
[post_date] => 2026-01-19 10:54:25
[post_date_gmt] => 2026-01-18 23:54:25
[post_content] => In the Barossa Valley, Travis Schiller FPS shows aged care is about teamwork, trust and better outcomes for residents.
What’s it like working as a pharmacist in the Barossa?
While only an hour or so from the city, the Barossa has all the advantages of a regional location.
It’s a privilege to serve in a community with such a rich history; the people and
the community embrace you and appreciate all you can do for them. When I first moved there, I was very quickly invited to present at service clubs and assist with local health programs.
There’s such a diversity of opportunity and organisations in the area willing
to explore new ways to improve care for the community. I was fortunate to have the support of local residential aged care facilities (RACFs) to explore new ways of supporting their staff and residents and improving medicines-related outcomes.
How did you get your start in aged care?
I developed a passion for it through my honours project on Residential Medication Management Reviews (RMMRs) post-hospital discharge.
I was fortunate to be involved in further projects, and with the support of a local facility, began spending regular time there in 2013.
I was not only interested in the on-site function but how a supply pharmacy and RACF could work together to achieve the best outcomes for residents – where pharmacy staff became part of the team rather than external contractors.
I was also fortunate to be involved in the initial Aged Care On-Site Pharmacist (ACOP) trials, and later assisted in a mentoring program where three privately funded pharmacists worked on site in aged care before the government-funded program rolled out.
Creating a mentoring environment allowed us to combine the benefits of experience in aged care with the enthusiasm, skill and knowledge of the next generation of pharmacists.
Working with independent RACFs meant we could act as the glue that helped them support one another locally, which we facilitated through regional Medication Advisory Committees.
What are the challenges of being embedded in aged care?
The ‘us and them’ mentality I had seen in many sites was the biggest challenge, with rigorous incident reporting leaving supply pharmacies as easy scapegoats.
Reinforcing to facility staff that I was there to assist them, that we were one team, and that our purpose was the residents’ benefit led to a culture shift and better outcomes. Up until the government funded the ACOP measure, funding was always an issue; and the current levels of funded remuneration will continue to be a barrier to the best and brightest taking up and staying in these roles.
What advice do you have for ECPs?
It’s often said that pharmacy is at a crossroads. While this sentiment is generally considered negative, I think it’s a great analogy for the exciting opportunities and options available to those starting out their careers.
There are many roads to travel professionally. When it’s time for a change, take a different route – explore, find what you love and do it. If it doesn’t exist as a career path, create it.
Get involved in the industry through conferences, organisations and networks – and definitely find a mentor, or a few. There are so many great people willing to share their time and knowledge, so don’t be afraid to tap into it.
Where do you see the pharmacy profession evolving?
With increasing role diversity, broader scope and rapid advances in technology, it’s an exciting time to be a pharmacist.
I’d love to see us truly recognised and valued as integral members of the broader healthcare system for all that we do.
I can only see our roles expanding as the population ages, with more specialised positions becoming the norm. Ageing at home will be the next big challenge – and we need to work out how best to support our communities through it.
A day in the life of Travis Schiller FPS, pharmacist owner, Nuriootpa, Barossa Valley, South Australia.
| 7.30 am | Prepare for the day Quick check of emails, paperwork and messages for staffing issues for the day ahead. |
| 8.30 am | Medication advisory meeting Catch up with aged care staff, GPs and the aged care on-site pharmacist. Discuss a recent issue with completing drugs of dependence recording systems and improve procedures to prevent recurrences. Talk about residents removing patches. Also discuss alternate therapies, alternate patch placement and improved surveillance. |
| 10.00 am | In the mall Visit our ‘The Barossa Pharmacist In the Mall’ pharmacy, touch base with rostering coordinator, check in with staff and see if the dispensary needs anything. Check prescriptions in the dispensary and counsel patients. Administer two COVID-19 vaccinations, and consult with other patients on hay fever and skincare treatment options. |
| 12.00 pm | In the main street Visit our nearby sister site, ‘The Barossa Pharmacist In the Main Street’, check with staff and provide lunch cover in the dispensary. Packing client arrives with a change to medicines, so organise the profile change and adjust packs. Warfarin commenced for one of our regulars. Sat with them and discussed the new medicine and their concerns. Receive a prescription for a packing client that doesn’t match profile; phone the GP to clarify. |
| 2.00 pm | Aged care supply and training Assist in the pharmacy with regular daily non-packed aged care orders for the afternoon, checking medication profiles and chart changes from the GP round. Also work through a Certificate III module with a pharmacy assistant after their S2/S3s schedules training. |
| 6.00 pm | Evening meeting Attend the local Health Care Advisory Committee meeting to discuss opportunities to fund facilities for our local hospitals. |
| 7.30 pm | Home time Hopefully make it home in time to say goodnight to my three girls, then relax and review the day with my wife. |
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31175
[post_author] => 235
[post_date] => 2026-01-14 09:29:29
[post_date_gmt] => 2026-01-13 22:29:29
[post_content] => From roles in governance, research and education, hospital pharmacists are practicing to an increasingly advanced scope. But evolving roles must be grounded in clinical need, organisational priorities and demonstrable impact.
At the Alfred Hospital in Melbourne, pharmacists have long practised to an expanded scope. Pharmacy roles include running disease management and anticoagulation services, writing chart corrections in partnership with medical staff and participating in emergency responses such as stroke callouts.
Behind every expanded role is a clear need, said Professor Michael Dooley MPS, Director of Pharmacy at Alfred Health and Chair of PSA’s Hospital Pharmacy Practice Community of Specialty Interest.
‘When you start to think about offering new services or evolving roles, you need to ask why,’ he told attendees at a session on the topic at PSA25 in August. If there isn’t a reason beyond “I’m interested”, then why are you doing it?’
To expand their services, hospital pharmacy departments must also align with organisational and broader governmental priorities, Prof Dooley said.
‘If I want more staff or more support, I need to talk in the language of the organisation and make sure we address issues that are organisational priorities.’
This approach has enabled pharmacists at the Alfred to move beyond dispensary-based roles and embed themselves at key points along the patient journey.
Around 50–60% of pharmacists at the Alfred are allocated to a clinical unit and work as part of the medical team, Prof Dooley explained. A further 20% work in operational roles, such as in sterile suites, dispensaries and outpatients, while around 5% focus on medicines use and safety, and others are in education and training.
‘We don’t centre all our staff in dispensaries,’ Prof Dooley said. ‘The opportunities for people to practise across a whole range of things are really diverse. That happened because we first identified a clinical need and then investigated whether it was within our scope of practice.
‘Anything you’re considering taking forward, you need to think about it in terms of impact.’
Training pathways for hospital pharmacists
For hospital pharmacists looking to expand their scope, there are now multiple pathways available.
‘It used to be said that you had to do your internship at a hospital pharmacy to get in the door,’ said Lauren Foley, Lead Pharmacist for Learning and Development at Alfred Health. ‘But what’s happened over the last 5–10 years is we now have these diverse entry points. It’s about finding the pathway that works for you.’
As well as an internship, pharmacists can undertake foundation residencies, which provide generalist training over a 2-year period.
‘At the 3- to 7-year mark, you can start thinking about specialisation or a registrar training program, which develops advanced practice in a particular area or scope,’ Ms Foley said. ‘There are also external training and credentialing programs.’
Ms Foley highlighted the stroke credentialing program at Alfred Health as an example of expanded practice driven by patient need.
‘It was identified that patients weren’t receiving thrombolysis within the 60-minute timeframe that we know preserves brain function,’ she said. ‘So the question became: how can we improve that outcome?’
One solution was embedding a pharmacist into those stroke teams who see patients in the emergency department. The role of pharmacists was to obtain the best possible medication history, make recommendations around the management of acute blood pressure and facilitate the early administration of thrombolysis.
‘the initiative led to an improvement in the number of patients who received thrombolysis within 60 minutes. That’s how we know the role is making a difference.’
lauren foley
To prepare pharmacists, credentialing requirements include a minimum level of experience, targeted education, assessment, and an objective structured clinical examination with a neurologist and senior pharmacist.
‘We needed to equip pharmacists with the knowledge, the expertise and the confidence to go there and be part of those stroke calls,’ Ms Foley said. ‘It's quite a confronting scenario so you need pharmacists who can make confident and appropriate recommendations in a life-or-death situation.’
Importantly, the impact of the program has been measurable.
‘There has been research showing the initiative led to an improvement in the number of patients who received thrombolysis within 60 minutes,’ Ms Foley said. ‘That’s how we know the role is making a difference.’
Beyond the bedside
The scope of practice for hospital pharmacists goes further than direct patient care. Pharmacists lead medicines safety initiatives, antimicrobial stewardship programs, and research and education programs.
‘There's also an emerging role in hospital pharmacy departments for stewardship pharmacists, who have a particular role or area of interest, and they become the go-to person for specialised advice, whether it be for anticoagulants [or] antibiotics,’ Ms Foley said.
In every role, pharmacists need to work closely with colleagues from other specialties, Prof Dooley said.
‘You need multidisciplinary support. You can't do any of these things by yourself. If you're interested in developing your services, you have to do that as part of the team.’
This is one of Ms Foley’s favourite parts of the job. ‘There are opportunities to have a chat with the physio or the speech pathologist, to ask the dietitian why they’ve recommended a particular type of enteral nutrition, and to be with the doctor on the ward round. It’s so important to learn from people who are specialists in their area.’
Join PSA’s Communities of Specialty Interest to connect, collaborate and advance your specialty practice.
[post_title] => Hospital pharmacists’ scope is expanding
[post_excerpt] => From roles in governance, research and education, hospital pharmacists are practicing to an increasingly advanced scope.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => hospital-pharmacists-scope-is-expanding
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-14 14:06:46
[post_modified_gmt] => 2026-01-14 03:06:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31175
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => Hospital pharmacists’ scope is expanding
[title] => Hospital pharmacists’ scope is expanding
[href] => https://www.australianpharmacist.com.au/hospital-pharmacists-scope-is-expanding/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31179
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31167
[post_author] => 11758
[post_date] => 2026-01-12 13:52:34
[post_date_gmt] => 2026-01-12 02:52:34
[post_content] => PSA’s ASPIRE Palliative Care Foundation Training Program gives pharmacists the skills to deliver this vital care – to patients and families alike.
Australia’s population is living to a greater age, which in turn has led to increased need for end-of-life care. It’s estimated that demand for palliative care in Australia will rise by 50% between now and 2035, and double by 2050.
Until now, most pharmacists have had to navigate complex medication regimes and challenging family conversations – with little to no formal training during university studies.
To help bridge this gap, PSA launched the ASPIRE Palliative Care Foundation Training Program last year. The course, delivered online across eight modules, aims to equip pharmacists with essential, proactive skills – not only for patients, but for the family and carers who also require significant support.
‘The ASPIRE training reminded me that palliative care is not just the last few days of life, it’s actually the weeks, months and sometimes even years after a person has a diagnosis that means that their life is going to be shortened,’ said Amy Gibson MPS, a consultant clinical pharmacist and educator who works as an on-site pharmacist in an Aspect Health aged care facility outside Brisbane.
[caption id="attachment_31171" align="aligncenter" width="500"]
Amy Gibson MPS[/caption]
‘Palliative care is about making plans to keep that patient as comfortable and in the best health possible for the time they’ve got left – often it’s heart failure and chronic lung disease patients.’
A holistic approach
Before completing the ASPIRE training program, Ms Gibson said she ‘didn’t have a lot of skills around palliative care’.
‘I knew about what we refer to as the “Core Four” medicines. I knew about anticipatory prescribing and making sure you’ve got something on hand for pain management, agitation and so on,’ she said.
‘But I hadn’t really thought so much about those social aspects of having conversations with people to find out what actual issues they were having, and how as a pharmacist you could support them.’
While not designed to prepare pharmacists to specialise in palliative care, the ASPIRE training course explores a broad range of topics around end-of-life issues, from symptom management and interdisciplinary palliative care to the role of the pharmacist across everything from medicine management to bereavement and self-care.
The holistic approach of the training resonated with Ms Gibson. ‘There was a lot of psychosocial education, including around what palliative care patients experience and also what that’s like for their families,’ she said. ‘It reinforced cultural perspectives, particularly for [Aboriginal and Torres Strait Islander] peoples, acknowledging that different cultures deal with death and dying in diverse ways and there’s not a one-size-fits-all approach.’
The ASPIRE training puts the carers’ perspectives in place, said Ruilin Ng MPS, a consultant pharmacist and credentialled diabetes educator based in suburban Adelaide. ‘A lot of the time, people are so focused on the person in care that the person around them is not given as much attention.’
The list of drugs a carer picks up can also be a vital clue for pharmacists to open a conversation. ‘A simple, “How are you”, or “How’s it going”, goes a long way,’ she said.
‘Otherwise family members or carers sometimes fall through the cracks. They may not have the support of a counsellor because obviously the focus is not on them.’
The training also reminds pharmacists of their critical role in being proactive around the most fundamental parts of palliative care, Ms Gibson said.
‘There are cases when people have trouble even physically getting to the pharmacy, saying “We need someone to be with Dad 24/7” for example,’ she said. ‘They don’t have the headspace to say that [coming to the pharmacy] isn’t working for them and might not even realise we can arrange delivery, so there’s a lot of emphasis on the practical measures we can provide.’
Medicine management when it’s most critical
As most people aim to spend their final days at home or in an aged care facility rather than in a hospital, the training helps prepare pharmacists to support them, including the specifics of palliative care medicines management.
‘We can assist [prescribers] in knowing what medicines should be prescribed for comfort measures and what medicines should be ceased because they're no longer serving a purpose,’ Ms Gibson said.
This also includes making sure the right medicines are available. ‘If your loved one is in pain or quite agitated, you don’t want to be told you’ve got to wait 24 hours because it’s not in stock,’ Ms Gibson said. ‘The training encourages community pharmacies to have these key palliative [care] medicines on hand so patients’ families don’t have to run around the town trying to find supplies.’
In her aged care role, Ms Gibson works closely with registered nurses to maintain an imprest supply. ‘This is emergency stock, including palliative care medicines, that they might need to use before the next delivery from the pharmacy comes,’ she said.
‘If an after-hours GP comes at night and says, “We need to start this patient on a morphine syringe driver”, we’ve got some ready to go – they don’t have to wait until the order arrives at 3.00 pm the next afternoon. I help the nurses monitor that stock. And if we’re running low, I make sure the order goes through to our supply pharmacy in plenty of time.’
The skills Ms Gibson honed through the ASPIRE training program recently helped her treat a resident with advanced dementia who was admitted to hospital but discharged back to the aged care facility with little warning.
‘She was close to the end of [her] life and they’d ceased everything but the palliative [care] medicines, anticipating she wouldn’t [live] more than a couple of days,’ she said.
‘As soon as I saw the message that she was expected back later that day, I checked that we had enough morphine and midazolam to make sure she could be administered those medicines as soon as she got back, because she was unlikely to be sent back to us with [a supply of] those medications.
‘Her doses were escalating quickly and over the next couple of days I made sure we stayed on top of stock levels, putting orders into the pharmacy regularly to make sure we weren't going to run out overnight.’
The ASPIRE training reinforced the importance of this approach. ‘At the very end of life, the situation can deteriorate quickly, with a change in condition often meaning a change in dose,’ Ms Gibson said.
‘We don’t want people to be uncomfortable and you don’t want to wait a day for the order to arrive. There’s a real need to anticipate what’s going to happen.’
Care after the end
When end of life arrives for the patient, it’s those left behind who need care.
‘The ASPIRE training puts the carer’s perspectives in place, [and] is a very good introduction to the bereavement aspect’ Ms Ng said. ‘[You learn] how to start the conversation, because it’s not an easy topic.’
Pharmacists have an important role in acknowledging carer grief and bereavement after the death of a loved one, and signposting to further support if required.
Keen to learn more about palliative care? Pharmacists, students and interns can enrol free of charge in the Training Plan: ASPIRE Palliative Care Foundation Training Program.
[post_title] => At the end of life, pharmacists are essential
[post_excerpt] => PSA’s ASPIRE Palliative Care Foundation Training Program gives pharmacists the skills to deliver this vital care – to patients and families.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => at-the-end-of-life-pharmacists-are-essential
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-13 09:48:57
[post_modified_gmt] => 2026-01-12 22:48:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31167
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => At the end of life, pharmacists are essential
[title] => At the end of life, pharmacists are essential
[href] => https://www.australianpharmacist.com.au/at-the-end-of-life-pharmacists-are-essential/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31169
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31160
[post_author] => 11750
[post_date] => 2026-01-12 11:56:10
[post_date_gmt] => 2026-01-12 00:56:10
[post_content] => Compounding environments must be designed to minimise contamination risk – including keeping meal breaks well away from the bench.
For most, the image of a typical ‘behind the counter’ pharmacy environment is not one of expansive space. Instead, it’s a compact and busy environment where almost every inch is occupied by something essential for us to do our job. There’s the dispensary itself, an area where medicines are compounded, and usually, another space for staff to take their well-deserved lunch break, too.
Separation of compounding and lunch areas is essential, not only for keeping crumbs out of capsules, but to ensure compounded medicines are free from contamination, consistently meet quality standards and for maintaining the safety of staff.1,2
Why is it important?
Pharmacists have a legal and professional responsibility to ensure compounding occurs in an environment that has been adequately designed, equipped and resourced.2
Compounding practices should be informed by relevant guidelines and standards for Good Manufacturing Practice (GMP), which reinforce the importance of prohibiting food and drink in compounding areas.2,3 These areas need to be clean and orderly to protect ingredients and compounded medicines from microbial and particulate contamination, throughout all stages of compounding.3 Grabbing a quick bite between batches could put medicine quality, staff and patient safety at risk.
How should a compounding area be organised?
Requirements vary across pharmacy premises depending on the complexity of the compounding being conducted. Facilities and equipment must comply with relevant Commonwealth and state or territory legislation, relevant regulatory authority requirements and Australian standards.4
Some key considerations for compounding areas include that4,5:
Complex compounding activities will require more specialised facilities and equipment.4 Non-sterile complex compounding should ideally occur in a dedicated laboratory separated from other parts of the pharmacy by floor-to-ceiling walls, with a door for entry and exit.4 It’s important to remember that if the laboratory is accessible by the public, the door should be lockable.4
Risk assessments are useful tools to determine whether compounding areas and equipment are suitable and safe for the medicines being compounded.2 If an issue is identified, remember it’s important to bring this to the attention of the person responsible for the premises, to allow for corrective actions to be implemented.
See the Australian Pharmaceutical Formulary (APF) Compounding decision support and risk assessment tool for guidance.
Everyone is entitled to a lunch break. Designating a separate space for meals away from compounding areas reduces contamination risk and maintains GMP standards for compounded medicines, staff and patients.
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31190
[post_author] => 3410
[post_date] => 2026-01-19 11:11:00
[post_date_gmt] => 2026-01-19 00:11:00
[post_content] => A recent systematic review published in the BMJ has reignited debate about what happens when patients stop taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related GLP-1–based incretin therapies.
The analysis found that weight often returns quickly once treatment is discontinued – in some cases faster than with other weight-loss interventions.
And it’s not just weight that rebounds. Cardiometabolic risk markers, including blood pressure, blood glucose and blood lipids, were also found to revert towards pre-treatment levels.
As prescribing of these medicines continues to rise, the findings raise a broader question: should patients be starting these medicines in the first place?
AP spoke with experts to unpack the evidence.
Weight regain predictable, but not the real problem
Professor Clare Collins, Professor of Nutrition and Dietetics at the University of Newcastle, said the pattern of rapid weight regain following cessation was entirely unsurprising.
‘This is exactly what you would expect,’ she said.
[caption id="attachment_31196" align="aligncenter" width="400"]
Professor Clare Collins[/caption]
For Prof Collins, the findings reinforce a core principle of chronic disease management: when an effective treatment is withdrawn, the condition it was controlling usually returns.
‘If someone stops taking antihypertensives, what happens? Their blood pressure goes back up,’ she said.
‘While predictable, the deterioration back to baseline is why we need to be thinking much more carefully about what is needed for long-term maintenance.'
Prof clare collins
While weight regain attracts headlines, Prof Collins said the more clinically concerning signal is the deterioration in metabolic markers once treatment ceases.
‘While predictable, the deterioration back to baseline is why we need to be thinking much more carefully about what is needed for long-term maintenance.’
Not a sign of treatment failure
Associate Professor Trevor Steward, Director of the Melbourne School of Psychological Sciences’ Brain and Mental Health Hub, agrees that the rebound effect reflects how GLP-1 RA medicines work, rather than a failure of the drugs or patient behaviour.
Instead of creating permanent physiological change, GLP-1 RAs amplify hormonal signals that already exist in the body – particularly those involved in appetite regulation, digestion and satiety. The benefits seen during treatment depend on sustained exposure to these hormones.
[caption id="attachment_31197" align="aligncenter" width="400"]
Associate Professor Trevor Steward[/caption]
‘That's why we see this rapid rebound effect of people experiencing weight gain when they stop using them, because there’s no longer increased circulating levels of hormones impacting their different body systems,’ A/Prof Steward said.
However, the mechanisms behind the accelerated regain are not yet fully understood.
‘Some indications are that while these newer medications help people lose weight faster, they may cause a stronger slingshot effect,’ he said.
Prof Collins points to emerging evidence suggesting incretin therapies cross the blood–brain barrier, influencing reward pathways linked to appetite and environmental cues to eat.
‘For example, if you go to the supermarket for a loaf of bread and come back with donuts too – that’s what’s referred to as “food noise”,’ she said. ‘Some people say this [noise] really goes down when using these therapies.’
When treatment is withdrawn, the surrounding food environment can quickly reassert itself. This is where tapering, behavioural support and nutrition strategies become critical.
‘It may be that people are more receptive to maintenance support programs as they’re tapering or finding out what their maintenance medication dose is,’ she said. ‘If they’re aware of that point, they’ll recognise when the food noise starts again.’
Nutrition: the missing variable
Prof Collins recently led a systematic review which highlighted that changes in dietary intake and nutrition remain largely invisible in incretin trials.
‘Of all the phase three trials, only two actually measured and reported what people ate,’ she said.
Most trials provided standardised advice but did not collect data on dietary intake, leaving clinicians to infer how appetite suppression, nausea and early satiety shaped eating patterns over time.
‘They mostly worked with people to identify dietary changes that would remove about 2,000 kilojoules a day – enough to trigger weight loss,’ she said.
But reduced intake doesn’t automatically equate to improved diet quality or nutrient adequacy, with micronutrient deficiencies and loss of lean mass emerging if nutrition isn’t actively monitored.
With frequent patient contact, Prof Collins believes pharmacists are uniquely placed to identify emerging problems, intervene early and support appropriate referral to dietitians for medical nutrition therapy.
‘[And] if pharmacy staff are trained, they can say, “Hang on a minute, you need to talk to the pharmacist”.’
The University of Newcastle also has a suite of resources pharmacists could direct patients to, including a healthy eating quiz and obesity management podcast, available here.
When visible deterioration or rapid weight loss appears, referral becomes essential. ‘Once you think, “this person is fading before our eyes”, that’s when you alert the GP and refer to a dietitian,’ Prof Collins said.
Supporting persistence with therapy also plays a role in outcomes.
‘The main benefit isn’t weight – it’s metabolic health,’ she said. ‘Helping people manage [adverse] effects supports continuation.’
As weight loss occurs, pharmacists should also be alert to the need to review other medicines.
‘If someone is dropping weight rapidly, blood sugars and blood pressure can fall,’ she said. ‘There are also rare but potentially severe complications – pancreatitis, gallstones, bowel obstruction and non-arteritic anterior ischaemic optic neuropathy,’ she said. ‘Staying well hydrated is critical – urine should look straw-coloured.’
Playing the long game
A/Prof Steward said there’s now sufficient evidence to normalise weight regain after cessation. And given the established risks associated with long-term obesity, he suggests continued therapy may represent a lower-risk option for some patients.
‘As we know, having a very high BMI for a long period of time confers its own levels of risks in terms of cardiovascular disease and other issues,’ he said. ‘So [many clinicians] think it's worth staying on these [medicines] long term as opposed to the potential risk of weight [regain].’
For people with repeated cycles of weight loss and regain, A/Prof Steward said GLP-1 RAs are increasingly being understood as potentially lifelong treatments – similar to medicines used for other chronic conditions.
‘Clinicians want clearer evidence around tapering and maintenance – and right now, they’re operating in the dark.'
A/prof trevor steward
‘I recently had a conversation with someone who has lost over 50 kilograms three times in her life,’ he said. ‘After a sustained period of lifestyle change, the weight still comes back. She would rather stay on these medicines for life than put her body through that cycle again.’
As use expands, A/Prof Steward emphasised the importance of clarifying intent and expectations before treatment begins.
‘It's really important to have that conversation with a pharmacist or GP about whether they want to make that commitment to potentially taking these long term,’ he said.
This also creates space to explore motivations for initiating therapy.
‘A lot of people are taking these medications for non-health related reasons, e.g. if they have a wedding coming up,’ A/Prof Steward said.
‘So it's really worth emphasising that these medications are serious drugs that impact the entire body, and it's not something that should be frivolously taken for the purpose of losing a few kg in a month – only to just have them come back.’
While Prof Collins doesn’t think the BMJ findings should deter prescribing, she said cost must be contextualised early – particularly as maintenance strategies continue to evolve. This may include lower costs associated with food and other medicines.
‘If you're improving your weight-related health, how much would medical visits have cost if your health hadn’t improved?’ she said. ‘These medications are a long-term cost, like a car or a mobile phone. We also don't yet know whether, for some people, they may be able to have periods where they don't take it and then reinitiate at lower doses again.’
With potential PBS listings and new formulations on the horizon, A/Prof Steward said clinical messaging will need to evolve alongside the evidence.
‘Over half a million Australians are now taking these medicines,’ he said. ‘Clinicians want clearer evidence around tapering and maintenance – and right now, they’re operating in the dark.’
For more information, read the AP CPD article Weight loss management.
[post_title] => Are GLP-1 RAs becoming lifelong medicines?
[post_excerpt] => A recent systematic review has reignited debate about what happens when patients stop taking GLP-1 RAs and related incretin therapies.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => are-glp-1-ras-becoming-lifelong-medicines
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-19 15:35:39
[post_modified_gmt] => 2026-01-19 04:35:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31190
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => Are GLP-1 RAs becoming lifelong medicines?
[title] => Are GLP-1 RAs becoming lifelong medicines?
[href] => https://www.australianpharmacist.com.au/are-glp-1-ras-becoming-lifelong-medicines/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31192
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31184
[post_author] => 3410
[post_date] => 2026-01-19 10:54:25
[post_date_gmt] => 2026-01-18 23:54:25
[post_content] => In the Barossa Valley, Travis Schiller FPS shows aged care is about teamwork, trust and better outcomes for residents.
What’s it like working as a pharmacist in the Barossa?
While only an hour or so from the city, the Barossa has all the advantages of a regional location.
It’s a privilege to serve in a community with such a rich history; the people and
the community embrace you and appreciate all you can do for them. When I first moved there, I was very quickly invited to present at service clubs and assist with local health programs.
There’s such a diversity of opportunity and organisations in the area willing
to explore new ways to improve care for the community. I was fortunate to have the support of local residential aged care facilities (RACFs) to explore new ways of supporting their staff and residents and improving medicines-related outcomes.
How did you get your start in aged care?
I developed a passion for it through my honours project on Residential Medication Management Reviews (RMMRs) post-hospital discharge.
I was fortunate to be involved in further projects, and with the support of a local facility, began spending regular time there in 2013.
I was not only interested in the on-site function but how a supply pharmacy and RACF could work together to achieve the best outcomes for residents – where pharmacy staff became part of the team rather than external contractors.
I was also fortunate to be involved in the initial Aged Care On-Site Pharmacist (ACOP) trials, and later assisted in a mentoring program where three privately funded pharmacists worked on site in aged care before the government-funded program rolled out.
Creating a mentoring environment allowed us to combine the benefits of experience in aged care with the enthusiasm, skill and knowledge of the next generation of pharmacists.
Working with independent RACFs meant we could act as the glue that helped them support one another locally, which we facilitated through regional Medication Advisory Committees.
What are the challenges of being embedded in aged care?
The ‘us and them’ mentality I had seen in many sites was the biggest challenge, with rigorous incident reporting leaving supply pharmacies as easy scapegoats.
Reinforcing to facility staff that I was there to assist them, that we were one team, and that our purpose was the residents’ benefit led to a culture shift and better outcomes. Up until the government funded the ACOP measure, funding was always an issue; and the current levels of funded remuneration will continue to be a barrier to the best and brightest taking up and staying in these roles.
What advice do you have for ECPs?
It’s often said that pharmacy is at a crossroads. While this sentiment is generally considered negative, I think it’s a great analogy for the exciting opportunities and options available to those starting out their careers.
There are many roads to travel professionally. When it’s time for a change, take a different route – explore, find what you love and do it. If it doesn’t exist as a career path, create it.
Get involved in the industry through conferences, organisations and networks – and definitely find a mentor, or a few. There are so many great people willing to share their time and knowledge, so don’t be afraid to tap into it.
Where do you see the pharmacy profession evolving?
With increasing role diversity, broader scope and rapid advances in technology, it’s an exciting time to be a pharmacist.
I’d love to see us truly recognised and valued as integral members of the broader healthcare system for all that we do.
I can only see our roles expanding as the population ages, with more specialised positions becoming the norm. Ageing at home will be the next big challenge – and we need to work out how best to support our communities through it.
A day in the life of Travis Schiller FPS, pharmacist owner, Nuriootpa, Barossa Valley, South Australia.
| 7.30 am | Prepare for the day Quick check of emails, paperwork and messages for staffing issues for the day ahead. |
| 8.30 am | Medication advisory meeting Catch up with aged care staff, GPs and the aged care on-site pharmacist. Discuss a recent issue with completing drugs of dependence recording systems and improve procedures to prevent recurrences. Talk about residents removing patches. Also discuss alternate therapies, alternate patch placement and improved surveillance. |
| 10.00 am | In the mall Visit our ‘The Barossa Pharmacist In the Mall’ pharmacy, touch base with rostering coordinator, check in with staff and see if the dispensary needs anything. Check prescriptions in the dispensary and counsel patients. Administer two COVID-19 vaccinations, and consult with other patients on hay fever and skincare treatment options. |
| 12.00 pm | In the main street Visit our nearby sister site, ‘The Barossa Pharmacist In the Main Street’, check with staff and provide lunch cover in the dispensary. Packing client arrives with a change to medicines, so organise the profile change and adjust packs. Warfarin commenced for one of our regulars. Sat with them and discussed the new medicine and their concerns. Receive a prescription for a packing client that doesn’t match profile; phone the GP to clarify. |
| 2.00 pm | Aged care supply and training Assist in the pharmacy with regular daily non-packed aged care orders for the afternoon, checking medication profiles and chart changes from the GP round. Also work through a Certificate III module with a pharmacy assistant after their S2/S3s schedules training. |
| 6.00 pm | Evening meeting Attend the local Health Care Advisory Committee meeting to discuss opportunities to fund facilities for our local hospitals. |
| 7.30 pm | Home time Hopefully make it home in time to say goodnight to my three girls, then relax and review the day with my wife. |
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31175
[post_author] => 235
[post_date] => 2026-01-14 09:29:29
[post_date_gmt] => 2026-01-13 22:29:29
[post_content] => From roles in governance, research and education, hospital pharmacists are practicing to an increasingly advanced scope. But evolving roles must be grounded in clinical need, organisational priorities and demonstrable impact.
At the Alfred Hospital in Melbourne, pharmacists have long practised to an expanded scope. Pharmacy roles include running disease management and anticoagulation services, writing chart corrections in partnership with medical staff and participating in emergency responses such as stroke callouts.
Behind every expanded role is a clear need, said Professor Michael Dooley MPS, Director of Pharmacy at Alfred Health and Chair of PSA’s Hospital Pharmacy Practice Community of Specialty Interest.
‘When you start to think about offering new services or evolving roles, you need to ask why,’ he told attendees at a session on the topic at PSA25 in August. If there isn’t a reason beyond “I’m interested”, then why are you doing it?’
To expand their services, hospital pharmacy departments must also align with organisational and broader governmental priorities, Prof Dooley said.
‘If I want more staff or more support, I need to talk in the language of the organisation and make sure we address issues that are organisational priorities.’
This approach has enabled pharmacists at the Alfred to move beyond dispensary-based roles and embed themselves at key points along the patient journey.
Around 50–60% of pharmacists at the Alfred are allocated to a clinical unit and work as part of the medical team, Prof Dooley explained. A further 20% work in operational roles, such as in sterile suites, dispensaries and outpatients, while around 5% focus on medicines use and safety, and others are in education and training.
‘We don’t centre all our staff in dispensaries,’ Prof Dooley said. ‘The opportunities for people to practise across a whole range of things are really diverse. That happened because we first identified a clinical need and then investigated whether it was within our scope of practice.
‘Anything you’re considering taking forward, you need to think about it in terms of impact.’
Training pathways for hospital pharmacists
For hospital pharmacists looking to expand their scope, there are now multiple pathways available.
‘It used to be said that you had to do your internship at a hospital pharmacy to get in the door,’ said Lauren Foley, Lead Pharmacist for Learning and Development at Alfred Health. ‘But what’s happened over the last 5–10 years is we now have these diverse entry points. It’s about finding the pathway that works for you.’
As well as an internship, pharmacists can undertake foundation residencies, which provide generalist training over a 2-year period.
‘At the 3- to 7-year mark, you can start thinking about specialisation or a registrar training program, which develops advanced practice in a particular area or scope,’ Ms Foley said. ‘There are also external training and credentialing programs.’
Ms Foley highlighted the stroke credentialing program at Alfred Health as an example of expanded practice driven by patient need.
‘It was identified that patients weren’t receiving thrombolysis within the 60-minute timeframe that we know preserves brain function,’ she said. ‘So the question became: how can we improve that outcome?’
One solution was embedding a pharmacist into those stroke teams who see patients in the emergency department. The role of pharmacists was to obtain the best possible medication history, make recommendations around the management of acute blood pressure and facilitate the early administration of thrombolysis.
‘the initiative led to an improvement in the number of patients who received thrombolysis within 60 minutes. That’s how we know the role is making a difference.’
lauren foley
To prepare pharmacists, credentialing requirements include a minimum level of experience, targeted education, assessment, and an objective structured clinical examination with a neurologist and senior pharmacist.
‘We needed to equip pharmacists with the knowledge, the expertise and the confidence to go there and be part of those stroke calls,’ Ms Foley said. ‘It's quite a confronting scenario so you need pharmacists who can make confident and appropriate recommendations in a life-or-death situation.’
Importantly, the impact of the program has been measurable.
‘There has been research showing the initiative led to an improvement in the number of patients who received thrombolysis within 60 minutes,’ Ms Foley said. ‘That’s how we know the role is making a difference.’
Beyond the bedside
The scope of practice for hospital pharmacists goes further than direct patient care. Pharmacists lead medicines safety initiatives, antimicrobial stewardship programs, and research and education programs.
‘There's also an emerging role in hospital pharmacy departments for stewardship pharmacists, who have a particular role or area of interest, and they become the go-to person for specialised advice, whether it be for anticoagulants [or] antibiotics,’ Ms Foley said.
In every role, pharmacists need to work closely with colleagues from other specialties, Prof Dooley said.
‘You need multidisciplinary support. You can't do any of these things by yourself. If you're interested in developing your services, you have to do that as part of the team.’
This is one of Ms Foley’s favourite parts of the job. ‘There are opportunities to have a chat with the physio or the speech pathologist, to ask the dietitian why they’ve recommended a particular type of enteral nutrition, and to be with the doctor on the ward round. It’s so important to learn from people who are specialists in their area.’
Join PSA’s Communities of Specialty Interest to connect, collaborate and advance your specialty practice.
[post_title] => Hospital pharmacists’ scope is expanding
[post_excerpt] => From roles in governance, research and education, hospital pharmacists are practicing to an increasingly advanced scope.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => hospital-pharmacists-scope-is-expanding
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-14 14:06:46
[post_modified_gmt] => 2026-01-14 03:06:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31175
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => Hospital pharmacists’ scope is expanding
[title] => Hospital pharmacists’ scope is expanding
[href] => https://www.australianpharmacist.com.au/hospital-pharmacists-scope-is-expanding/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31179
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31167
[post_author] => 11758
[post_date] => 2026-01-12 13:52:34
[post_date_gmt] => 2026-01-12 02:52:34
[post_content] => PSA’s ASPIRE Palliative Care Foundation Training Program gives pharmacists the skills to deliver this vital care – to patients and families alike.
Australia’s population is living to a greater age, which in turn has led to increased need for end-of-life care. It’s estimated that demand for palliative care in Australia will rise by 50% between now and 2035, and double by 2050.
Until now, most pharmacists have had to navigate complex medication regimes and challenging family conversations – with little to no formal training during university studies.
To help bridge this gap, PSA launched the ASPIRE Palliative Care Foundation Training Program last year. The course, delivered online across eight modules, aims to equip pharmacists with essential, proactive skills – not only for patients, but for the family and carers who also require significant support.
‘The ASPIRE training reminded me that palliative care is not just the last few days of life, it’s actually the weeks, months and sometimes even years after a person has a diagnosis that means that their life is going to be shortened,’ said Amy Gibson MPS, a consultant clinical pharmacist and educator who works as an on-site pharmacist in an Aspect Health aged care facility outside Brisbane.
[caption id="attachment_31171" align="aligncenter" width="500"]
Amy Gibson MPS[/caption]
‘Palliative care is about making plans to keep that patient as comfortable and in the best health possible for the time they’ve got left – often it’s heart failure and chronic lung disease patients.’
A holistic approach
Before completing the ASPIRE training program, Ms Gibson said she ‘didn’t have a lot of skills around palliative care’.
‘I knew about what we refer to as the “Core Four” medicines. I knew about anticipatory prescribing and making sure you’ve got something on hand for pain management, agitation and so on,’ she said.
‘But I hadn’t really thought so much about those social aspects of having conversations with people to find out what actual issues they were having, and how as a pharmacist you could support them.’
While not designed to prepare pharmacists to specialise in palliative care, the ASPIRE training course explores a broad range of topics around end-of-life issues, from symptom management and interdisciplinary palliative care to the role of the pharmacist across everything from medicine management to bereavement and self-care.
The holistic approach of the training resonated with Ms Gibson. ‘There was a lot of psychosocial education, including around what palliative care patients experience and also what that’s like for their families,’ she said. ‘It reinforced cultural perspectives, particularly for [Aboriginal and Torres Strait Islander] peoples, acknowledging that different cultures deal with death and dying in diverse ways and there’s not a one-size-fits-all approach.’
The ASPIRE training puts the carers’ perspectives in place, said Ruilin Ng MPS, a consultant pharmacist and credentialled diabetes educator based in suburban Adelaide. ‘A lot of the time, people are so focused on the person in care that the person around them is not given as much attention.’
The list of drugs a carer picks up can also be a vital clue for pharmacists to open a conversation. ‘A simple, “How are you”, or “How’s it going”, goes a long way,’ she said.
‘Otherwise family members or carers sometimes fall through the cracks. They may not have the support of a counsellor because obviously the focus is not on them.’
The training also reminds pharmacists of their critical role in being proactive around the most fundamental parts of palliative care, Ms Gibson said.
‘There are cases when people have trouble even physically getting to the pharmacy, saying “We need someone to be with Dad 24/7” for example,’ she said. ‘They don’t have the headspace to say that [coming to the pharmacy] isn’t working for them and might not even realise we can arrange delivery, so there’s a lot of emphasis on the practical measures we can provide.’
Medicine management when it’s most critical
As most people aim to spend their final days at home or in an aged care facility rather than in a hospital, the training helps prepare pharmacists to support them, including the specifics of palliative care medicines management.
‘We can assist [prescribers] in knowing what medicines should be prescribed for comfort measures and what medicines should be ceased because they're no longer serving a purpose,’ Ms Gibson said.
This also includes making sure the right medicines are available. ‘If your loved one is in pain or quite agitated, you don’t want to be told you’ve got to wait 24 hours because it’s not in stock,’ Ms Gibson said. ‘The training encourages community pharmacies to have these key palliative [care] medicines on hand so patients’ families don’t have to run around the town trying to find supplies.’
In her aged care role, Ms Gibson works closely with registered nurses to maintain an imprest supply. ‘This is emergency stock, including palliative care medicines, that they might need to use before the next delivery from the pharmacy comes,’ she said.
‘If an after-hours GP comes at night and says, “We need to start this patient on a morphine syringe driver”, we’ve got some ready to go – they don’t have to wait until the order arrives at 3.00 pm the next afternoon. I help the nurses monitor that stock. And if we’re running low, I make sure the order goes through to our supply pharmacy in plenty of time.’
The skills Ms Gibson honed through the ASPIRE training program recently helped her treat a resident with advanced dementia who was admitted to hospital but discharged back to the aged care facility with little warning.
‘She was close to the end of [her] life and they’d ceased everything but the palliative [care] medicines, anticipating she wouldn’t [live] more than a couple of days,’ she said.
‘As soon as I saw the message that she was expected back later that day, I checked that we had enough morphine and midazolam to make sure she could be administered those medicines as soon as she got back, because she was unlikely to be sent back to us with [a supply of] those medications.
‘Her doses were escalating quickly and over the next couple of days I made sure we stayed on top of stock levels, putting orders into the pharmacy regularly to make sure we weren't going to run out overnight.’
The ASPIRE training reinforced the importance of this approach. ‘At the very end of life, the situation can deteriorate quickly, with a change in condition often meaning a change in dose,’ Ms Gibson said.
‘We don’t want people to be uncomfortable and you don’t want to wait a day for the order to arrive. There’s a real need to anticipate what’s going to happen.’
Care after the end
When end of life arrives for the patient, it’s those left behind who need care.
‘The ASPIRE training puts the carer’s perspectives in place, [and] is a very good introduction to the bereavement aspect’ Ms Ng said. ‘[You learn] how to start the conversation, because it’s not an easy topic.’
Pharmacists have an important role in acknowledging carer grief and bereavement after the death of a loved one, and signposting to further support if required.
Keen to learn more about palliative care? Pharmacists, students and interns can enrol free of charge in the Training Plan: ASPIRE Palliative Care Foundation Training Program.
[post_title] => At the end of life, pharmacists are essential
[post_excerpt] => PSA’s ASPIRE Palliative Care Foundation Training Program gives pharmacists the skills to deliver this vital care – to patients and families.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => at-the-end-of-life-pharmacists-are-essential
[to_ping] =>
[pinged] =>
[post_modified] => 2026-01-13 09:48:57
[post_modified_gmt] => 2026-01-12 22:48:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=31167
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => At the end of life, pharmacists are essential
[title] => At the end of life, pharmacists are essential
[href] => https://www.australianpharmacist.com.au/at-the-end-of-life-pharmacists-are-essential/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 31169
[authorType] =>
)
td_module_mega_menu Object
(
[post] => WP_Post Object
(
[ID] => 31160
[post_author] => 11750
[post_date] => 2026-01-12 11:56:10
[post_date_gmt] => 2026-01-12 00:56:10
[post_content] => Compounding environments must be designed to minimise contamination risk – including keeping meal breaks well away from the bench.
For most, the image of a typical ‘behind the counter’ pharmacy environment is not one of expansive space. Instead, it’s a compact and busy environment where almost every inch is occupied by something essential for us to do our job. There’s the dispensary itself, an area where medicines are compounded, and usually, another space for staff to take their well-deserved lunch break, too.
Separation of compounding and lunch areas is essential, not only for keeping crumbs out of capsules, but to ensure compounded medicines are free from contamination, consistently meet quality standards and for maintaining the safety of staff.1,2
Why is it important?
Pharmacists have a legal and professional responsibility to ensure compounding occurs in an environment that has been adequately designed, equipped and resourced.2
Compounding practices should be informed by relevant guidelines and standards for Good Manufacturing Practice (GMP), which reinforce the importance of prohibiting food and drink in compounding areas.2,3 These areas need to be clean and orderly to protect ingredients and compounded medicines from microbial and particulate contamination, throughout all stages of compounding.3 Grabbing a quick bite between batches could put medicine quality, staff and patient safety at risk.
How should a compounding area be organised?
Requirements vary across pharmacy premises depending on the complexity of the compounding being conducted. Facilities and equipment must comply with relevant Commonwealth and state or territory legislation, relevant regulatory authority requirements and Australian standards.4
Some key considerations for compounding areas include that4,5:
Complex compounding activities will require more specialised facilities and equipment.4 Non-sterile complex compounding should ideally occur in a dedicated laboratory separated from other parts of the pharmacy by floor-to-ceiling walls, with a door for entry and exit.4 It’s important to remember that if the laboratory is accessible by the public, the door should be lockable.4
Risk assessments are useful tools to determine whether compounding areas and equipment are suitable and safe for the medicines being compounded.2 If an issue is identified, remember it’s important to bring this to the attention of the person responsible for the premises, to allow for corrective actions to be implemented.
See the Australian Pharmaceutical Formulary (APF) Compounding decision support and risk assessment tool for guidance.
Everyone is entitled to a lunch break. Designating a separate space for meals away from compounding areas reduces contamination risk and maintains GMP standards for compounded medicines, staff and patients.
CPD credits
Accreditation Code : CAP2405AMVS
Group 1 : 0.75 CPD credits
Group 2 : 1.5 CPD credits
This activity has been accredited for 0.75 hours of Group 1 CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist's CPD plan, which can be converted to 0.75 hours of Group 2 CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.
Get your weekly dose of the news and research you need to help advance your practice.
Protected by Google reCAPTCHA v3.
Australian Pharmacist is the official journal for Pharmaceutical Society of Australia Ltd.